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Chapter 1
General introduction and outline of the thesis
Inez K.B. Slagt, Jan N.M. IJzermans, Türkan Terkivatan
Department of Surgery, Erasmus MC, 
University Medical Center Rotterdam, The Netherlands
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KIDNEY TRANSPLANTATION
The kidney is an essential organ that plays an crucial role in acid-base balance, sodium 
and potassium balance, calcium metabolism, regulation of blood pressure, red blood 
cell synthesis and excretion of metabolites. Kidney diseases may result in kidney failure 
with the requirement of kidney replacement therapy like dialysis. Hemodialysis and 
peritoneal dialysis may extend patient survival but does not cure the kidney failure. 
Kidney transplantation is considered the optimal kidney replacement therapy for 
patients with end stage kidney failure, resulting in decreased morbidity, improved 
quality of life and higher costs effectiveness when compared to dialysis.
History of kidney transplantation
In the early years of experimental kidney transplantation, donor kidneys were placed in 
the thigh with cutaneous ureterostomy drainage or in the iliac fossa with drainage by 
ureteroureterostomy to the recipient native ureter. In January 1951, Rene Kuss placed a 
donor kidney into the iliopelvic region of the recipient with cutaneous ureterostomy.1, 2 
Soon thereafter another French surgical team established the concept that a kidney placed 
in the iliac fossa provides a short ureter with possibilities for drainage to the bladder. 
Although these early attempts of kidney transplantation resulted in failure, Joseph 
Murray and John Hartwell Harrison completed the first successful kidney transplantation 
on identical twins in Boston on December 23, 1954.3 The recipient was prepared with 
hemodialysis, and monozygosity was confirmed by the successful exchange of full 
thickness skin grafts between the twins. The left donor kidney was transplanted in the 
right recipient’s iliac fossa, and a intravesical ureteroneocystostomy with a submucosal 
tunnel was established. A small polyethylene catheter was placed up the transplant 
ureter and was suprapubicly externalized. After renal vascularization by doctor Murray, 
doctor Harrison assisted with the urinary tract reconstruction. The kidney functioned 
directly after transplantation and the patient was discharged on day 37 postoperative. 
The kidney function maintained good and was functioning until cardiac death 8 years 
later occur.4 This successful transplantation between identical twins enhanced the 
opinion that the pelvic location with possibilities of bladder drainage was the most 
physiological and natural position for the kidney graft.1 Nevertheless, the intervention 
of adequate immunosuppressive therapy in the 1960s enabled kidney transplantation 
on a larger scale. 
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Ureteroneocystostomy
Although the position and the vascular anastomoses of the transplanted kidney have 
remained unchanged over time, multiple techniques have been described for managing 
the urinary continuity. Techniques like ureteroneocystostomy, ureteropyelostyomy and 
uretero-ureterostomy have been used. 
Two types of ureteroneocystostomy are common, the intravescial or transvesical 
anastomosis (Figure 1) and the extravesical anastomosis (Figure 2). The intravesical 
anastomosis, first described by Politano-Leadbetter, was frequently used during the early 
days of transplantation.5, 6 However, this method is associated with intrusive bladder 
dissection and therefore an extravesical approach was designed.7 This extravesical 
anastomosis, first described by Lich-Gregoir, was presented at the German Congress of 
Surgery in April 1961.7 Many modifications of the extravesical anastomosis have been 
developed, like Shanfield, Taguchi and Barry techniques.1 
Other techniques to obtain urinary continuity, ureteropyelostomy and uretero-
ureterostomy, have good outcomes, but these techniques are reserved for reconstruction 
situations. Ureteroneocystostomy is widely accepted for establishing urinary continuity, 
and is associated with the lowest number of complications. However, no consensus 
exists regarding superiority of either the intravesical anastomosis or the extravesical 
anastomosis.
Urological complications
One of the main concerns after kidney transplantation is a major urological complication, 
such as leakage and stenosis of the ureter. These complications are often related to the 
junction site of the ureteroneocystostomy with a reported incidence up to 10% and require 
additional radiological or even surgical intervention. If signs of leakage or obstruction 
appear, a percutaneous nephrostomy (PCN) is placed to insure a consistent urinary drainage. 
Risk factors contributing to urological complications have been described rarely in 
the literature, but include donor and recipient characteristics. Donor related factors 
like deceased or living, problems during graft retrieval, multiple renal arteries, age 
or diabetes mellitus could influence the graft quality. Recipient factors like anatomy, 
vascular status, need of dialysis, type of ureteroneocystostomy or stent placement may 
also contribute to development of urological complications.
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Figure 1 Intravesical anastomosis with a stent placed in the pelvis of the kidney and externalized as a 
suprapubic catheter.
Figure 2 Extravesical anastomosis with a stent placed in the pelvis of the kidney and externalized as a 
suprapubic catheter. 
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AIM AND OUTLINE OF THE THESIS
This thesis includes studies that address various aspects related to urological 
complications after kidney transplantation. Surgical techniques are compared, risk 
factors are determined, costs are calculated, and experience in scare cases of kidney 
transplantation are described.
Ureteroneocystostomy technique
No consensus exists on the preferred operative technique of the ureteroneocystostomy. 
Two most common techniques are the intravesical anastomosis and the extravesical 
anastomosis. In chapter two a systematic review and meta-analysis is performed on 
existing literature comparing these two anastomoses.
To reach the best level of evidence on the topic of type ureteroneocystostomy we 
performed a Randomized Controlled Trial (RCT) on the intravesical anastomosis versus 
the extravesical anastomosis. This study is presented in chapter three.
Identification and costs of urological complications
Risk factors contributing to the prevalence of urological complications need to be 
determined. Factors associated with urological complications are donor and recipient 
characteristics. Regarding the differences in organ retrieval between deceased and living 
donor kidney transplantation and the extended donor criteria, we wanted to determine risk 
factors for urological complications in deceased donor kidney transplantation. Chapter four 
describes an analysis to identify independent risk factors for urological complications.
Kidney transplantation has a great advantage on patient’s quality of life in comparison 
to dialysis. Also, kidney transplantation results in decreased medical costs compared to 
dialysis. However, urological complications following transplantation incur additional 
costs, especially in case of major urological complications. In these cases additional 
radiological interventions or even surgical interventions are often inevitable. Chapter 
five represents the long-term clinical outcome of patients requiring a radiological or 
surgical ureter reconstruction with an additional cost analysis. 
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Kidney transplantation in a reconstructed urinary tract
Formerly, patients that underwent a urinary reconstructive procedure have been excluded 
from kidney transplantation, because it was thought that the bladder contributed to 
the destruction of the native kidneys and would destruct the transplant graft. Literature 
describes only 0.2-2.3% of adult patients with a reconstructed urinary tract receiving 
a kidney transplantation. In chapter six we describe our long-term outcome of these 
patients with a reconstructed urinary tract receiving a kidney transplant.
General discussion and future perspective, summary and conclusions
In chapter seven the results of the studies performed in this thesis are discussed. Finally, 
chapter eight contains summaries in English and Dutch. 
14 Chapter 1
REFERENCES
 1 Veale JL, Yew J, Gjertson DW, et al. Long-term comparative outcomes between 2 common 
ureteroneocystostomy techniques for renal transplantation. J Urol (2007);177:632-636. 
 2 Kuss R Human renal transplantation memories 1951 to 1981 History of Transplantation: Thirty-
Five Recollections. Regents of the University of California 1991; 3-4 and 39-40.
 3 Harrison JH, Merrill JP, Murray JE Renal homotransplantation in identical twins. Surg Forum. 
(1956);6:432. 
 4 Barry JM, Murray JE The first human renal transplants. J Urol (2006);176:888-890. 
 5 Politano VA, Leadbetter WF An operative technique for the correction of vesicoureteral reflux. J 
Urol (1958);79:932-941. 
 6 Secin FP, Rovegno AR, Marrugat RE, Virasoro R, Lautersztein GA, Fernandez H Comparing 
Taguchi and Lich-Gregoir ureterovesical reimplantation techniques for kidney transplants. J Urol 
(2002);168:926-30. 
 7 Gregoir W the Surgical Treatment of Congenital Vesico-Ureteral Reflux Le Traitement Chirurgical 
Du Reflux Vesico-Ureteral Congenital. Acta Chir Belg (1964);63:431-439. 


Chapter 2
Intravesical versus extravesical 
ureteroneocystostomy in kidney transplantation: 
A systematic review and meta-analysis
Inez K.B. Slagt, Karel W.J. Klop , Jan N.M. IJzermans , Türkan Terkivatan
Department of Surgery, Erasmus MC, 
University Medical Center, Rotterdam, the Netherlands
Transplantation. 2012 Dec 27;94(12):1179-84.
18 Chapter 2
ABSTRACT
Introduction
Urological complications are still a major problem postoperatively with a reported 
incidence of up to 30%, associated with significant morbidity, mortality, prolonged 
hospital stay and high medical costs. To date, there is no evidence favouring either 
an extravesical or an intravesical approach. The purpose of this systematic review and 
meta-analysis is to determine if an intravesical or extravesical anastomosis in kidney 
transplantation is to be preferred. 
Patients and Methods
Comprehensive searches were conducted in PubMed, Embase and the Cochrane Library. 
Reference lists were searched manually. The methodology was in accordance with the 
PRISMA statement. Two randomized controlled trials and seventeen cohort studies were 
identified.
Results
Based on the meta-analysis, outcome was in favour of the extravesical anastomosis. 
A relative risk (RR) for stenosis of 0.67 (confidence interval (CI), 0.48-0.93; p=0.02), for 
leakage 0.55 (CI 0.39-0.80; p=0.001) for the total number of urological complications 
0.56 (CI 0.41-0.76; p<0.001) and for haematuria of 0.41 (CI 0.22-0.76; p=0.005) was 
demonstrated. 
Conclusion
Based on our results, we conclude that there is evidence in favour of the extravesical 
ureteroneocystostomy for having a smaller amount of urological complications in 
kidney transplantation. 
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INTRODUCTION
Kidney transplantation is considered the gold standard in treatment of patients with end 
stage renal disease (ESRD), resulting in a decrease in morbidity, better quality of life and 
higher cost effectiveness when compared with hemo- or peritoneal dialysis.1 During the 
1950s, the surgical technique for kidney transplantation was developed, engrafting the 
kidney extraperitoneally in the iliac fossa with vascular anastomosis to the iliac vessels.2-4 
Several variations for achieving urinary continuity of the transplanted kidney include 
ureteroneocystostomy, ureteropyelostomy, uretero-ureterostomy and cutaneous 
ureterostomy. Of these various techniques, the ureteroneocystostomy appears to be 
most widely accepted and is associated with the lowest number of complications.5 
Nevertheless, urological complications including urinary tract infections are still a 
major problem postoperatively with a reported incidence of up to 30%, associated 
with significant morbidity, mortality and prolonged hospital stay.6 Major urological 
complications, mostly existing of stenosis or leakage with a reported incidence beneath 
10%, are frequently related to the junction site of the ureteroneocystostomy and often 
require percutaneous or surgical intervention.7
In literature, there is no consensus on the preferred operative technique for the 
ureteroneocystostomy. The most common techniques for ureteroneocystostomy are 
the intra- or transvesical approach, first described by Politano-Leadbetter (PL)8, and the 
extravesical approach as described by Lich-Gregoir (LG).9 Most studies focus on a single 
technique and are retrospectively performed. Furthermore, a lot of the literature on the 
surgical techniques and outcome of ureteroneocystostomy has been published in the 
early years of kidney transplantation.5, 7-9 The aim of the present study was to assess the 
superiority of either the intra- or extravesical anastomosis in kidney transplantation, 
after a systematic review and when systematically analyzing and reviewing the literature.
METHODS
All aspects of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
(PRISMA)10 statement were followed.
Literature search strategy
A systematic search of PubMed, Embase and the Cochrane library was performed. Articles 
relevant to kidney transplantation and ureteroneocystostomy with in the limits “human 
related” and “English language” were selected. The MeSH term ‘kidney transplantation’ 
was used in Pubmed. Other key words used were ‘ureteroneocystostomy’, ‘Politano-
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Leadbetter’, ‘Lich-Gregoir’, ‘intravesical’, ‘extravesical’, ‘surgery’ and ‘anastomosis’. Manual 
reference checks of accepted papers in recent reviews and included papers were 
performed to supplement the electronic searches.
Literature screening
Studies were evaluated on relevance by two independent researchers (IKBS, KWJK) 
before inclusion. A random cross-check was performed by a senior researcher (TT). 
Study selection was accomplished by three levels of screening (Figure 1). At level 1, 
studies were excluded by title and abstract for the following reasons: case series, case 
reports, letters, editorials, comments, reporting on children, uretero-ureterostomy, two 
ureters or kidney transplantation combined with pancreas transplantation. At level 
2, the full text of studies accepted at level 1 was reviewed for relevance according to 
the same criteria. Specific attention was paid to a comparison between intravesical 
and extravesical anastomoses or double published data. Stent placement, primary or 
re-transplantation and living versus deceased donor did not interfere with our selection.
Data extraction and critical appraisal
Data, design and population were extracted from all included studies. Raw data on 
the amount of patients undergoing the different techniques had to be available for 
inclusion. Studies that included two different types of intra- or extravesical anastomosis 
were excluded. The level of evidence of each study was scored using the Oxford Centre 
for Evidence-based Medicine Level of Evidence scale.11 The quality of each study was 
calculated using the Jadad-score12 for the randomized controlled trials and by the 
Newcastle-Ottawa Scale13 for all cohort studies.
Statistical analysis
Risk ratios (RR) and their 95% confidence interval (CI) were calculated from raw data with 
the intravesical anastomoses group as reference. A meta-analysis was performed with 
urological complications as outcome using Review Manager (RevMan) software (version 
5.1.4; The Nordic Cochrane Center Copenhagen, Denmark). Each study was weighted 
by sample size, not by quality. Statistical heterogeneity was explored by inspecting the 
forest plot, testing the Q (heterogeneity χ2) and the I2 statistics. Summary estimators of 
treatment effects were calculated using a random effects model with RR and its 95% 
CI. Overall effects were determined using the Z-test. End points were set on ‘stenosis’, 
‘leakage’, ‘total number of urological complications’, ‘haematuria’ and ‘urinary tract 
infection’. A subdivision was made for stenosis into ureterovesicaljunction (UVJ) stenosis 
and pyelo-ureterojunction (PUJ) stenosis. Leakage was divided into UVJ leakage and 
vesical leakage. To asses publication bias funnel plots were made.
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Level 1 Papers indentified  
after initial search  
n = 528  
Excluded based on title and 
abstract n = 447 
Level 2 Potentially relevant 
publications  
n = 81 
Included for review 
 n = 19 
Excluded based on full text 
n = 63 
Publications found in 
references n= 1 
 
Relevant publications  
n = 18 
 
Figure 1 PRISMA flowchart of the systematic literature search 
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Outline of surgical techniques
The PL anastomosis is created by performing a cystotomy on the anterior side to visualize 
the interior of the bladder and expose the trigone. A second cystotomy is performed 
to create a new ureteric orifice. The transplanted ureter is tunnelled submucosally for 
approximately 2 centimetres. The distal site is trimmed and spatulated anteriorly at an 
optimal length to ensure a tension free anastomosis. The distal ureter is sutured to the 
bladder mucosa with interrupted absorbable stitches. The cystotomy is closed in two 
layers to ensure a watertight anastomosis.
The LG anastomosis is created by performing a cystotomy for 2 to 3 centimetres on 
the anterolateral surface of the bladder dome to expose mucosa of the bladder wall. A 
small incision is made in the mucosa. The transplanted ureter is trimmed and spatulated 
posteriorly. The mucosa of the bladder is sutured to the ureteral end with interrupted 
absorbable sutures. The detrusor muscle is closed over the anastomosis to create a sub 
mucosal tunnel with an antireflux mechanism.
RESULTS
Of the 528 studies that were found after the initial search, eighteen were selected 
based on relevancy. One was added after a manual reference check of the included 
articles. These 19 manuscripts14-32 fell within the scope of the study (Figure 1) after 
full screening (PRISMA flowchart). All had a case distribution for intravesical versus 
extravesical ureteroneocystostomy after kidney transplantation, but outcome measures 
were diverse. The provided level of evidence on the Oxford Level of Evidence scale was 
level 4. Because of the low level of evidence and quality in the overall literature, no 
manuscript was excluded by the Jadad or Newcastle-Ottawa Scale. The meta-analysis 
was performed using studies with comparable outcome measures as described in the 
methods; study characteristics are presented in Table 1.
Stenosis 
Seventeen studies14-23, 25, 26, 28-32 reported on incidence of stenosis after 
ureteroneocystostomy with a total of 7681 patients, these studies were included for 
meta-analysis. The incidence of ureteral stenosis was significantly lower in the group of 
patients that received an extravesical anastomosis; RR 0.67 (95% CI 0.48-0.93; p=0.02) 
and I2 of 18% (Figure 2). The percentage of stenosis was 3.13% and 3.51% for respectively 
the group with an extravesical an intravesical anastomosis. Some of these studies also 
reported on the location of the stenosis; at the UVJ18, 23, 29, 30, the PUJ16, 18, 29, 30, 32 or (mid) 
ureteral.21, 29, 30 In these groups there was no statistical difference. The RR for a stenosis 
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at the UVJ was 0.63 (95% CI 0.29-1.37; p=0.25) with I2 of 33%, at the PUJ 0.55 (95% CI 
0.15-2.08; p=0.38) I2 43% and for a (mid) ureteral stenosis 0.56 (95% CI 0.20-1.58; p=0.27) 
I2 0% when comparing intravesical with extravesical ureteroneocystostomy.
Leakage
Urinary leakage was meta-analyzed in a total of 6410 patients from sixteen 
studies.14-17, 19, 20, 22, 23, 25-32 The incidence of urinary leakage was significantly lower in the 
group of patients that underwent an extravesical anastomosis with a RR of 0.55 (95% 
CI 0.39-0.80; p=0.001) and an I2 of 0% (Figure 3). The percentage of leakage was 1.65% 
for the extravesical and 3.25% for the intravesical anastomosis. A few studies pooled 
their data into UVJ leakage18, 21, 27, 28, 30 and vesical leakage.27, 28 The difference in number 
Table 1 References: 19 included studies
Reference Year Country Study type Group N Stent Outcome
Belli (10) 1985 Italy R cohort E: 115 I: 185 NM 1, 5, 8
Butterworth (11) 1997 UK P cohort E: 108 I: 140 E: stent I: no stent 1, 5, 8, 9, 10
Dohi (12) 1984 Japan U cohort E: 49 I: 21 NM 1, 3, 5, 8, 9
Georgiev (13) 2007 Swiss R cohort E: 348 I: 149 E: 162 stent on 
demand, 186 stent
I: stent on demand
1, 5, 8
Hakim (14) 1994 USA U cohort E: 773 I: 410 NM 1, 2, 3, 6, 8, 9
Hooghe (15) 1977 Belgium U cohort E: 133 I: 108 NM 1, 5
Jindal (16) 1994 USA U cohort E: 69 I: 116 NM 1, 5, 10
Leungwattanakij (17) 2000 Thailand U cohort E: 245 I: 93 NM 1, 4, 6, 8, 9
Li Marzi (18) 2005 Italy U cohort E: 260 I: 199 All double J stent 1, 5
Masahiko (19) 2000 Japan U cohort E: 225 I: 962 NM 1, 2, 5, 8
Mehta (20) 1978 UK U cohort E: 32 I: 87 E: NM I: no stent 8
Pleass (21) 1995 UK RCT E: 150 I: 150 E: 75 (no) stent 
I: 75 (no) stent
1, 5
Rizvi (22) 1996 Pakistan U cohort E: 148 I: 202 NM 1, 5, 8
Shah (23) 1987 India U cohort E: 125 I: 125 NM 5, 6, 7
Taghavi (24) 2003 Iran U cohort E: 68 I:  50 E: no stent I: no stent 1, 5, 6, 7
Thrasher (25) 1990 USA U cohort E: 160 I:  160 NM 1, 2, 3, 4, 5, 8, 9
Tillou (26) 2009 France R cohort E: 412 I:  265 95,5% stent 1, 2, 3, 4, 5, 6, 8
Waltke (27) 1982 USA Randomization 
on date
E: 72 I: 59 E: stent I: no stent 1, 5, 10
Whang (28) 2003 USA R cohort E: 1010 I: 67 E: stent I: no stent 1, 3, 5, 8
Randomization on date: randomization according to which surgeon was scheduled that date 
E: extravesical; I: intravesical; NM: not mentioned; N: number; R: retrospective; 
P: prospective; U: unclear; RCT: randomized control trial 
1 stenosis; 2 UVJ stenosis; 3 PUJ stenosis; 4 ureter stenosis; 5 leakage; 6 UVJ leakage; 7 vesical leakage; 
8 total number of urological complications; 9 haematuria; 10 urinary tract infection
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of UVJ leakage was statistically significant with a RR of 0.47 (95% CI 0.25-0.89; p=0.02) 
and an I2 of 0% in favour of the extravesical group while vesical leakage did not show a 
statistically significant difference, RR 0.13 (95% CI 0.02-1.04; p=0.05) with I2 0%.
Figure 2  Forest plot of stenosis rate in patients with an extravesical anastomosis versus those with an 
intravesical anastomosis. Risk ratio estimates, shown with 95% confidence intervals, were calculated using 
the random-effects model. The tilted square represents the overall treatment effect from the 17 pooled 
studies spanning the 95% confidence interval. 
Figure 3  Forest plot of leakage rate in patients with an extravesical anastomosis versus those with an 
intravesical anastomosis. Risk ratio estimates, shown with 95% confidence intervals, were calculated using 
the random-effects model. The tilted square represents the overall treatment effect from the 16 pooled 
studies spanning the 95% confidence interval.
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Total number of urinary complications
Twelve studies14-18, 21, 23, 24, 26, 29, 30, 32 reported on the total number of urological 
complications in a total of 6366 patients, and were included in our meta-analysis. The 
overall complication rate was significantly lower in the extravesical group with a RR of 
0.56 (95% CI 0.41-0.76, p<0.001) and an I2 of 44% (Figure 4). In percentages, 5.41% of 
these complications were seen in the extravesical group and 8.61% in the intravesical 
group.
Haematuria
The incidence of haematuria post transplantation was described in five 
studies15, 16, 18, 21, 29 with a total of 2159 patients. The meta-analysis showed significantly 
less frequent haematuria in the extravesical group with a RR of 0.41 (95% CI 0.22-0.76; 
p=0.005) and an I2 of 0%. Haematuria occurred in 1,20% and 4% in respectively the 
group of patients with an extravesical and intravesical anastomosis.
Urinary tract infections
Three studies (564 patients) 15, 20, 31 reported on urinary tract infections. These data were 
used for meta-analysis and no statistical difference was found between the intra- and 
extravesical group; RR 1.00 (95% CI 0.77-1.28 with p=0.97) and I2 of 0%. Urinary tract 
infections were seen in 26,9% of the extravesical group and in 28,25% of the intravesical 
group.
Figure 4  Forest plot of the total number of urological complication rate in patients with an extravesical 
anastomosis versus those with an intravesical anastomosis. Risk ratio estimates, shown with 95% 
confidence intervals, were calculated using the random-effects model. The tilted square represents the 
overall treatment effect from the 12 pooled studies spanning the 95% confidence interval.
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DISCUSSION
Despite a variety of urinary tract reconstruction techniques, postoperative urological 
complications are the most frequent technical adverse event in kidney transplantation. 
These complications are frequently associated with substantial morbidity and generate 
excess costs caused by re-admissions to the hospital, percutaneous (re-) interventions, 
imaging and surgical revisions of the ureteroneocystostomy.6
The present systematic review and meta-analysis reveals an advantage of the extravesical 
anastomosis in kidney transplantation compared to the intravesical anastomosis. 
A statistically significant difference was found in stenosis, leakage, total number of 
urological complications and haematuria (Figure 2, 3, 4), all in favour of the extravesical 
anastomosis. Regarding urinary tract infections, no significant difference was found 
between both types of anastomosis.
The majority of kidney transplant centers are performing an extravesical 
ureteroneocystostomy. However, no consensus exists in literature on the preferred 
technique. In 2010 a review of the literature on ureteroneocystostomy techniques in 
case of kidney transplantation was published by Kayler et al.3 A historical and technical 
description of four surgical techniques was provided and analyzed, focusing on 4 
specific urological complications; urinary leakage, ureteric obstruction, haematuria 
and symptomatic vesicoureteral reflux. Only two randomized controlled trials were 
performed and both showed a preference for the extravesical technique and the use of 
a prophylactic ureteric stent.25, 31
Appointed benefits of the extravesical ureteral anastomosis are shorter operation time 
due to simplicity of the technique, a shorter ureteral length and an additional reduced 
risk of ischemic injury to the distal ureter. Furthermore, the avoidance of a separate 
cystotomy with the additional risk of postoperative urinary leakage or ganglion injury 
(causing persistent neurogenic bladder dysfunction) is another advantage of an 
extravesical ureteroneocystostomy.3
Although this systematic review and meta-analysis provides important evidence for the 
technique of the ureteroneocystostomy in kidney transplantation, we must note some 
limitations of our study. The ureteroneocystostomy should provide a watertight, tension 
free and non-refluxing anastomosis with good passage of urine production and without 
obstruction.7, 20 Many modifications of the extravesical technique have been described, 
such as the use of running instead of interrupted sutures to create the ureteral mucosal 
anastomosis and tunnelling by sub mucosal blunt dissection instead of muscular 
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imbrications.3 All of these so-called modified techniques include extravesical access 
and an urothelial anastomosis. The use of these modified techniques may have biased 
the results of our meta-analysis. In addition, only Waltke et al.31 describe a radiographic 
contrast injection before stent removal. None of the included studies describe whether a 
pyelography has been performed routinely or only on indication after clinical suspicion 
for early urological complications. Inevitably, this must have influenced the rate of 
leakage or stenosis.
Likewise, the strong diversity in the use or no use of the different stent types, e.g. 
double-J or tube stenting, might have been an important confounder in our meta-
analysis. Since stenting may influence the healing of the anastomosis and thereby the 
total amount of urological complications. Proponents of stent placement advocate relief 
of the anastomosis because of the post-operative presence of oedema that may cause 
obstruction or leakage. The incidence of urinary tract infection was not increased in 
patients that receives a stent during kidney transplantation.25
The studies included in our meta-analysis were performed in different eras of 
immunosuppressive medication; this might be another confounding factor. Other 
nontechnical risk factors for the development of urological complications such as 
recipient age, number of renal arteries, and the occurrence of acute rejection episodes 
(not scored prospectively or independently) may have interfered with our analysis. 
Furthermore, the limited availability of prospective trials, selection bias may have 
occurred. For example, most of the described series included living and deceased donor 
grafts without having performed a multivariate analysis.
This systematic review and meta-analysis is the first step in providing a definite answer 
on superiority of either the extra- or intravesical techniques, accounting for urological 
complications and long-term outcome. To provide a superior level of evidence for either 
technique of ureteroneocystostomy, a sufficiently powered randomized controlled trial 
is recommended. Due to our systematic search, processing raw data and computed RR 
we managed to produce the best possible evidence. The results of our meta-analysis 
demonstrate superior results after extravesical anastomosis in kidney transplantation.
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ABSTRACT
Introduction
Urological complications after kidney transplantation are mostly related to the 
ureteroneocystostomy leading to significant morbidity, mortality, and high costs. The 
most commonly used techniques for the ureteroneocystostomy are the intravesical and 
the extravesical anastomosis No evidence in favor of one of these two anastomoses 
exists. Our aim was to determine the technique with the best outcome regarding 
urological complications in a randomized controlled trial (registered in the Netherlands 
Trial Register NTR2320). 
Patients and Methods
From October 2010 to December 2012, 200 consecutive recipients of a living donor 
kidney were randomized for either an intravesical or an extravesical anastomosis. The 
primary outcome was defined as placement of a percutaneous nephrostomy. 
Results
No significant differences were found in the number of percutaneous nephrostomy 
placements or ureter re-interventions between both groups. Nevertheless, significantly 
fewer urinary tract infections (p=0.04) occurred in the group with an extravesical 
anastomosis. Additionally, this anastomosis was performed significantly faster (p<0.001) 
compared to the intravesical anastomosis. 
Conclusion
There were no significant differences in the number of percutaneous nephrostomy 
placements after kidney transplantation comparing the two ureteroneocystostomy 
anastomoses. However, the extravesical approach was associated with significantly 
fewer urinary tract infections and might be preferable because of its surgical simplicity.
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INTRODUCTION
Kidney transplantation is considered to be the gold standard in treatment of patients 
with end stage renal disease (ESRD); it reduces mortality, morbidity, brings better 
quality of life and is more cost-effective than hemodialysis or peritoneal dialysis.1, 2 
The surgical technique has evolved since the first kidney transplantation. Nowadays, 
the kidney graft is often positioned in the iliac fossa with vascular anastomoses to the 
external iliac vessels.3-5 The most widely accepted technique for urinary continuity is the 
ureteroneocystostomy, which is associated with the lowest number of complications.6-8 
Although the overall complication rate is low, urological complications are still common 
after kidney transplantation, and may lead to increased morbidity, mortality, and 
prolonged hospital stay.9-11 Major urological complications, such as leakage and stenosis, 
are reported up to 10.5% and are often related to the ureteroneocystostomy.6, 12-17 
These complications usually require an external urinary drainage by a percutaneous 
nephrostomy catheter. Sometimes, even a surgical ureter reconstruction (neo-
ureteroneocystostomy) is required, increasing additional morbidity and costs.11, 14, 16, 18
The two most common techniques for ureteroneocystostomy are the intravesical 
approach, first described by Politano-Leadbetter19, and the extravesical approach as 
described by Lich-Gregoir.20 According to the literature, a preference for the extravesical 
anastomosis is reported for reasons such as the necessity for a shorter donor ureteral 
length, a shorter operation time (due to the simplicity of the technique) and avoidance 
of a separate cystotomy, which might cause an additional risk of post-operative 
urinary leakage, haematuria or ganglion injury.4, 5,13, 21, 22 However, most of the literature 
was published in the early years of kidney transplantation with a focus on a single 
technique and most of them were performed retrospectively.7, 19-21, 23 To determine 
which ureteroneocystostomy (intravesical or extravesical) is superior, we performed a 
randomized controlled clinical trial in living donor kidney transplantations. 
PATIENT AND METHODS
A previous retrospective study in our center showed an incidence of 22% percutaneous 
nephrostomy placements in case of live donor kidney transplantation, using the 
intravesical ureteroneocystostomy.11 For the purpose of power calculation we 
hypothesized that an extravesical ureteroneocystostomy would reduce the total number 
of percutaneous nephrostomy placements to 7%.24 With an alpha of 0.05 and beta of 
0.20 we calculated the need of 100 recipients in each study-arm, with a two-sided test. 
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Study design
After endotracheal intubation, we randomized two hundred consecutive recipients of 
a living donor kidney for either an intravesical (Politano-Leadbetter) or an extravesical 
ureteroneocystostomy (Lich-Gregoir). An independent statistician provided numbered 
sealed opaque envelopes, generated by a computer randomization list. To achieve a 
single blinded study, no participants or other care providers were informed about which 
anastomosis was performed. Exclusion criteria were age (<18 years), double ureter 
system of the donor kidney, robot assisted donor nephrectomy using the DaVinci Surgical 
System (because of an unknown surgical trauma to the ureter related to the technique 
itself ), absent native bladder of the recipient, and recipients that were included into 
another clinical trial of our department (general agreement that patients will not be 
included in two clinical trials at the same department). The Medical Ethical Committee at 
Erasmus MC University Medical Center approved the trial protocol (MEC-2009-385), and 
the study was registered in the Netherlands Trial Register (NTR2320) with a follow-up of 
1 year after transplantation, mainly because of one of the secondary end points, i.e. renal 
function at one year. In this manuscript, after post-hoc analysis, we report our 3 and 6 
months data to focus on the urological complications after kidney transplantation. The 
study was conducted in accordance with the Declaration of Helsinki. All patients gave 
informed consent and were included by the ‘intention to treat’ principle. 
Kidney transplantation
In our center, annually, over 150 kidney transplantations from living donors and more 
than 50 kidney transplantations from deceased donors are performed. Six certified 
transplant surgeons, all significantly experienced in both ureteroneocystostomy 
techniques, perform these procedures. After graft retrieval by either a laparoscopic 
donor nephrectomy or a hand assisted retroperitoneal donor nephrectomy, the kidney 
was transplanted extraperitoneally in the iliac fossa. Continuity of the urinary tract 
was established according to the randomized anastomosis. All recipients received a 
transurethral urinary catheter  (14 French) at the time of the transplantation, which 
was left in situ for 7 days. During the ureterovesical anastomosis, a stent (8 French) 
was inserted through the anastomosis with the tip positioned in the kidney pelvis and 
externalized suprapubically. The stent was removed after 10 days. Postoperative care 
was standardized. All patients underwent an ultrasonography and a MAG-3 scan one 
day after kidney transplantation. Immunosuppression consisted of 20 mg basiliximab 
intravenously on the day of surgery and day four after transplantation. Post-operative 
immunosuppression consisted of prednisolone (starting with 50 mg), tacrolimus (dose 
was titrated based on serum value) and mycofenolate mofetil (1000 mg twice a day). 
Prednisolone was tapered off and discontinued at four months after transplantation. 
A prophylactic daily dose of 480 mg cotrimoxazole was given to prevent urinary tract 
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infections during 7 days. Cefazoline was given perioperative. A daily standard dose 
of 12.000U heparin was given intravenously during the first 5 postoperative days. 
Valganciclovir treatment was given to patients at risk for CMV infection or reactivation. 
Initial episodes of acute rejection were treated with methylprednisolone; 1000mg a 
day for 3 days, ATG was given on indication. Kidney function was monitored daily by 
measuring serum creatinine and urine production during the post-transplant period. 
If anastomotic disruption or obstruction of the ureter was suspected, the graft was 
evaluated with an additional ultrasound to exclude fluid collections or hydronephrosis. 
Ureteroneocystostomy techniques
Intravesical anastomoses were created by performing a cystotomy on the anterior 
side to visualize the interior of the bladder and expose the trigone. A second (smaller) 
cystotomy was performed to create a new ureteric orifice. The ureter of the transplanted 
kidney was tunneled submucosally for approximately 2 centimeters. The distal end 
was trimmed and spatulated anteriorly at an optimal length to ensure a tension-free 
anastomosis. The distal ureter was sutured to the bladder mucosa with 5-6 interrupted 
absorbable stitches (PDS 5-0). The cystotomy was then closed with a running PDS 5-0 
suture to ensure a watertight anastomosis (Figure 1).
Extravesical anastomoses were created by performing a 1-2 centimeter cystotomy on 
the anterolateral surface of the bladder dome to expose the mucosa of the bladder 
wall. A small incision was made in the mucosa. The transplant ureter was trimmed 
and spatulated posteriorly. The mucosa of the bladder was sutured to the ureteral 
end with a running absorbable suture (PDS 5-0). The detrusor muscle was closed over 
the anastomosis using one or two interrupted absorbable sutures (PDS 4-0) to create 
a submucosal tunnel with an anti-reflux mechanism (Figure 2). Time to establish the 
ureteroneocystostomy was measured by the bladder incision as starting point and the 
last suture to complete the anastomosis as endpoint. 
Primary outcome
The primary outcome of our study was the incidence of percutaneous nephrostomy 
placement within 3 months after transplantation. A rise in serum creatinine level 
combined with a slight hydronephrosis or fluid collection on ultrasonography, leakage 
detected by the MAG-3 scan or proven by chemistry samples in case of extensive 
fluid production by the surgical site, drain or the wound, indicated and justified a 
percutaneous nephrostomy placement. Monitoring of the percutaneous nephrostomy 
position and imaging of the ureter was performed by an antegrade pyelography. If 
leakage of the ureteroneocystostomy was diagnosed with an antegrade pyelography, 
both a percutaneous nephrostomy and a urinary bladder catheter were placed until the 
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Figure 1 Intravesical anastomosis with a stent placed in the pelvis of the kidney and externalized as a 
suprapubic catheter.
Figure 2 Extravesical anastomosis with a stent placed in the pelvis of the kidney and externalized as a 
suprapubic catheter. 
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leakage stopped. In case the leakage was diagnosed shortly after transplantation (within 
24 hours), immediate surgical reconstruction was performed. If a total obstruction of the 
kidney graft ureter was diagnosed with an antegrade pyelography, surgical intervention 
was deemed inevitable. If the antegrade pyelography demonstrated a stenosed ureter 
but contrast reached the bladder, an endoscopic dilatation of the ureter was performed. 
Afterwards a percutaneous nephrocystostomy catheter is placed for 2 weeks. If the 
stenosis persisted on the long term, a surgical ureter reconstruction was indicated and 
performed by a transplant surgeon, together with an urologist. The method of ureter 
reconstruction depended on perioperative findings, including the degree of fibrosis, 
ureteral stricture length, aspect of the ureter and options for bladder mobilization.
Secondary outcome
Operation time of the kidney transplantation, graft ureteral length at time of ureteral 
implantation, time to establish the ureteroneocystostomy, type ureteroneocystostomy 
and possible procedure details (such as obesity, mechanical problems or bleedings) were 
listed during transplantation. All complications within 6 months after transplantation 
were prospectively scored: urinary tract infections (urine sample positive for bacteria), 
stent related complications, such as dysfunction and dislocation, tacrolimus toxicity 
(>15µg/l), rejection therapy (methylprednisolone), lymphoceles, urosepsis and surgical 
site infections. Surgical re-interventions and surgical ureteral reconstructions were 
registered during complete follow-up. Patients were tested for BK-viral infection in case 
of urological complications and 3 months after transplantation.
Statistical analysis
Statistical analysis was performed using IBM SPSS version 20.0 (IBM Corp., Armonk, NY, 
USA). Categorical variables were presented as number with percentage (%) and were 
tested using the Chi-square test. Continuous variables are presented as median with 
inter quartile range (IQR) and were tested with the Mann- Whitney U test. A p-value 
<0.05 was considered as statistically significant.
RESULTS
Baseline characteristics
Between October 2010 and December 2012, a total number of 305 patients were 
transplanted. A total of 55 patients did not meet our inclusion criteria. Another 50 patients 
were excluded based on no informed consent, impossibility of intravesical anastomoses 
or continued anti-coagulant use. Two hundred consecutive kidney transplantations 
were randomized to either an intravesical or extravesical ureteroneocystostomy 
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(Figure 3). Two equal groups were created without significant differences in baseline 
characteristics (Table 1) regarding donors and recipients. 
 
Assessed for eligibility (n=304) 
Excluded  (n=104) 
¨   Not meeting inclusion criteria (n=54) 
¨   Declined to participate (n=35) 
¨   Other reasons (n=15) 
Analysed  (n=99)  
 
Lost to follow-up (n=1)  
Transplantectomy 6 days after kidney 
transplantation 
Allocated to intravesical technique (n=100) 
¨ Received allocated intervention (n=100) 
¨ Did not receive allocated intervention (n=0) 
Lost to follow-up (n=0) 
Allocated to extravesical technique (n=100) 
¨ Received allocated intervention (n=100) 
¨ Did not receive allocated intervention (n=0) 
Analysed  (n=100) 
 
	  
Allocation 
Analysis 
Follow-Up 
3 months 
	  
Randomized (n=200) 
Enrollment 
Percutaneous nephrostomy (n=20) 
 
	  
Percutaneous nephrostomy (n=20)  
 
Results 
No interventions (n=15) Intervention (n=5) No interventions (n=15) Interventions (n=5) 
 
1 percutaneous nephrolithotomy 
2 surgical ureter 
reconstructions 
 
2 radiological 
ureter dilatations 
2 radiological ureter dilatations  
 
3 surgical ureter reconstructions 
Figure 3 Flow-chart INEX study
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Perioperative and postoperative outcome
Perioperative and postoperative measurements are presented in Table 2. The time to 
perform the ureteroneocystostomy was significantly shorter in the group of recipients 
with an extravesical anastomosis (median; 21 minutes intravesical versus 15 minutes 
extravesical) (p<0.001). There were no significant differences in ureteral length (median; 
9.5 cm intravesical versus 10 cm extravesical), total operation time (median; 132 minutes 
intravesical versus 128 minutes extravesical), blood loss during transplantation (median; 
250 ml intravesical versus 250 ml extravesical), and hospital admission time (median; 12 
days intravesical versus 12 days extravesical) between the two groups.
Primary outcome
A total number of 40 (20%) percutaneous nephrostomy placements were performed after 
kidney transplantation, 7 because of leakage and 33 because of hydronephrosis (Table 
3). The number of percutaneous nephrostomy placements was equally divided between 
both groups. The median time to the first percutaneous nephrostomy placement was 10 
days, with a range from 2 to 182 days after transplantation. One patient did not reach 
the primary endpoint of six months due to transplantectomy on day 6 postoperatively, 
because of acute vascular rejection.
Table 1 Baseline characteristics of the recipients and donors
Intravesical (n=100) Extravesical (n=100) p-value
Recipients
Male gender 63 68 0.46
Age (median) (IQR) 57.75 (46.35-63.90) 57.58 (47.29-64.40) 0.59
ASA (median) (IQR) 3.0 (3.0-3.0) 3.0 (3.0-3.0) 0.38
Pre-emptive transplantation 43 45 0.78
Total warm ischemia time (median in 
minutes) (IQR)
25 (21-29) 25 (22-29) 0.78
Cold ischemia time (median in 
minutes) (IQR)
143 (128-167) 145 (129-162) 0.70
Arterial reconstruction 14 19 0.34
Multiple transplantations (>1) 13 11 0.66
Donors
Male gender 41 40 0.89
Age (median) (IQR) 53.54 (41.68-65.0) 53.42 (42.98-62.63) 0.50
ASA (median) (IQR) 1.0 (1.0-2.0) 1.0 (1.0-2.0) 0.66
Laparoscopic  donor nephrectomy 66 67 0.94
IQR: inter quartile range, ASA: American Society of Anesthesiologists
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Secondary outcomes
Forty-six recipients (23%) developed a urinary tract infection (Escherichia coli or 
Enterococcus faecalis in the majority of cases, 76%), 29 in the group of patients with an 
intravesical and 17 with an extravesical ureteroneocystostomy (p=0.044). In 42 patients, 
stent dysfunction was suspected in the early postoperative phase: 19 patients with 
an intravesical and 23 patients with an extravesical ureteroneocystostomy (p=0.487). 
No significant differences between both groups were found with regard to urosepsis 
(p=0.248), surgical site infections (p=0.312), tacrolimus toxicity (p=0.669), rejection 
therapy (p=0.141) and lymphoceles (p=0.316) (Table 2). 
Table 2 Peroperative and postoperative outcomes
Intravesical (n=100) Extravesical (n=100) p-value
Ureteroneocystostomy time (median in 
minutes) (IQR)
21 (18-25) 15 (12-17) <0.001
Total time kidney transplantation (median 
in minutes) (IQR)
132 (117-151) 128 (109-147) 0.15
Blood loss during transplantation (median 
in ml) (IQR)
250 (150-500) 250 (100-395) 0.39
Ureteral length (median in cm) (IQR) 9.5 (8.63-10.73) 10.0 (8.63-11.0) 0.43
Hospital admission days (median) (IQR) 12 (10-15) 12 (10-17) 0.90
Urinary tract infections 29 17 0.04
Ureteral stent dysfunction 19 23 0.49
Urosepsis 5 2 0.25
Surgical site infection 1 3 0.31
Tacrolimus toxicity 45 42 0.67
Rejection therapy 22 14 0.14
Lymphocele 0 1 0.32
Surgical re-intervention 7 4 0.35
Median creatinine (µmol/L) 3 months after 
kidney transplantation (IQR)
134 (108-154) 125 (105-152) 0.41
Median creatinine (µmol/L) 6 months after 
kidney transplantation (IQR)
125 (111-152) 128 (102-156) 0.98
Follow-up (median in months) (IQR) 
(corrected for death and graft failure)
17.97 (12.31-27.33) 18.10 (12.80-27.79) 0.99
Graft failure  4  4 1.00
Death not related to kidney failure 1  5 0.10
IQR: inter quartile range, cm: centimeter, ml: milliliter
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Ten of the 200 recipients (5%) (5 intravesical/ 5 extravesical) required radiological ureter 
dilatation of the ureter or an additional surgical intervention (Table 3). In one case, a 
radiological ureter dilatation was performed without success, and an additional surgical 
reconstruction of the anastomosis was performed. Of the 10 patients requiring an 
additional intervention, only one patient was tested positive for BK-virus.
Surgical re-interventions during the same hospital stay of the transplantation were 
necessary in 12 recipients (7 intravesical/ 5 extravesical); 2 of these re-interventions 
were related to the ureteroneocystostomy (urine leakage from the wound). In 3 cases, 
a re-exploration was needed because of hemorrhage, 2 patients required a revision 
of their dialysis shunt because of shunt thrombosis, in 1 patient a transplantectomy 
was necessary because of therapy-resistant acute vascular rejection 6 days after 
transplantation, and 1 patient had a ruptured cyst in the transplanted kidney. In 1 
patient the ureteral stent had to be removed surgically since it was impossible to extract 
it according to protocol after releasing the fixation suture on day 10 postoperatively. One 
of the recipients with a primary non-function and a need for temporary hemodialysis 
had to be operated because of a bleeding from the puncture site of the dialysis shunt 
in the superficial femoral artery. One recipient developed an incisional hernia, requiring 
mesh repair, three months after transplantation.
Table 3 Characteristics of the recipients with a percutaneous nephrostomy placement
Intravesical 
(n=99)
Extravesical 
(n=100)
p-value
Percutaneous nephrostomy placement 20 20 -
Median time percutaneous nephrostomy placement 
(days post transplantation) (IQR)
9.5  
(5.0-14.75)
13.0  
(5.75-26.75)
0.53
Reason placement
 Leakage 4 3 0.70
 Hydronephrosis 16 17 0.85
Treatment of 40 recipients with a percutaneous nephrostomy
No re-intervention 15 15 -
Re-intervention 5 5 -
Type of re-intervention:
Surgical ureter reconstruction 2 3 0.65
Radiological ureter dilatation 2 2 -
Percutaneous nephrolithotomy 1 0 0.32
IQR: Inter Quartile Range
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Follow-up
Median graft follow-up was 18.1 months with a minimum of 6 days and a maximum of 
33.1months. A total of 8 grafts failed after transplantation after a median time of 11.6 
months, ranging from 6 to 908 days. One patient had an acute vascular rejection, three 
had an ongoing cellular rejection, two had recurrence of the primary disease (FSGS), one 
patient had a thrombotic microangiopathy eight months after transplantation, and one 
patient developed a graft failure at 10 months due to non-compliance. 
Six patients died after a median of 7.9 months after transplantation. One patient died 
because of an out-of-hospital cardiac arrest. Two patients died of metastasized cancer, 
diagnosed 22 and 26 months after transplantation. One patient died because of cardiac 
complications after a surgical reconstruction of the ureteroneocystostomy that had been 
performed 169 days after transplantation. One patient died because of a pre-existing 
liver failure, and one due to an ongoing urosepsis with bleeding in the gastrointestinal 
tract and pulmonary embolism leading to an unsuccessful resuscitation. There were no 
significant differences in graft and patient survival between patients with an intravesical 
or extravesical ureteroneocystostomy (Table 2). 
DISCUSSION 
In our randomized controlled clinical trial, we found no significant difference between 
the number of percutaneous nephrostomy placements in the group of recipients with an 
intravesical anastomosis or an extravesical anastomosis. The extravesical anastomosis, 
however, was associated with fewer urinary tract infections, and was performed 
significantly faster than the intravesical anastomosis. 
Previously, only two randomized controlled trials9, 25 have been performed to compare 
the two most common techniques for ureteroneocystostomy in kidney transplantation; 
being the intravesical approach and the extravesical approach. Besides the fact that these 
studies included mixed cases of living and deceased donor kidney grafts, one is in favor 
of the intravesical anastomosis because of an unacceptable high rate of obstructions 
in the extravesical group and the other is in favor of the extravesical anastomosis since 
there were less urological complications in this group. 
Furthermore, there are some other publications in the literature in favor of the 
extravesical anastomosis, such as a review by Kayler et al.4 and our own systematic 
review with additional meta-analysis.13 However, most of the studies that are included 
in these publications have several disadvantages such as retrospective design, small 
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cohort, and variation in surgical techniques. In addition they lack an overview of all 
urological complications, particularly the need for a percutaneous nephrostomy, which 
is often the first sign of a major urological complication.11, 21
Factors that may provoke urological complications, such as leakage and stenosis have 
not been identified in the literature. One possible factor is an insufficient blood supply 
to the ureter.10, 26, 27 Since the ‘golden triangle’ (the site confined by ureter, kidney and 
renal artery) is believed to be responsible for the blood supply of the ureter, excessive 
dissection during organ retrieval should be avoided.15 As failure of the blood supply 
might lead to necrosis of the distal ureter, a shorter ureter would be favorable during 
transplantation. Although it has been suggested that the length of the ureter is shorter 
in case of an extravesical anastomosis28 which might reduce the risk for urological 
complications, our study does not support this; ureteral length was the same in both 
types of anastomosis (Table 2). 
An important finding in our study is the higher rate of urinary tract infections after an 
intravesical anastomosis. One might argue that there is more surgical manipulation and 
dissection of the bladder when performing an intravesical ureteroneocystostomy, given 
the larger cystotomy, which causes bladder mucosa injury5 with a potentially higher 
risk for infections. Furthermore, the knots of the interrupted sutures are situated at the 
internal mucosal surface of the bladder in case of the intravesical ureteroneocystostomy; 
this might be an explanation for the higher incidence of urinary tract infections in this 
group.
In our randomized controlled trial, twenty percent of all recipients of a kidney graft 
from a living donor had a urological complication, as defined by percutaneous 
nephrostomy placement. We realize that we do have a high percentage of percutaneous 
nephrostomy placements, especially compared to the literature. This might be 
explained by the postoperative protocol for kidney transplant recipients in our clinic. 
We notice a low threshold to place a percutaneous nephrostomy, as this is considered 
a minimally invasive event. Even a slight hydronephrosis on ultrasonography leads 
to a percutaneous nephrostomy placement, either for therapeutically benefit, or 
as diagnostic tool before performing a biopsy. In addition, it is a fact that collecting 
data prospectively results in accurate and complete databases. Inevitably, this is the 
reason that in randomized controlled trials complication rates might be higher than 
percentages that are documented in other kind of publications. Despite the number of 
percutaneous nephrostomy placements, only 10 recipients (5%) underwent radiological 
ureter dilatation or surgical ureter reconstruction, which is comparable to in the 
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literature.14 Graft and patient survival were comparable between both groups, and also 
in consistency with the literature.
Although the total operation time was not significantly different between the two 
groups, the time needed to establish an extravesical ureteroneocystostomy (median; 15 
minutes, IQR (12-17) was significantly shorter than for an intravesical approach (median; 
21 minutes, IQR 18-25) (p<0.001) (Table 2), which is also supported by literature.5 The 
surgical simplicity of this approach is a benefit in both performing and teaching. A 
shorter learning curve to perform the ureteroneocystostomy is an advantage in case of 
surgical transplant trainees. 
Based on our results, we conclude that there is no significant difference in the number 
of urological complications as defined by percutaneous nephrostomy placement 
when comparing the two most commonly used intravesical and extravesical 
ureteroneocystostomy techniques. However, as the extravesical approach is associated 
with fewer urinary tract infections and with a time-sparing simplicity of the surgical 
technique, it may be advocated as first choice.
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ABSTRACT
Introduction 
Urological complications after kidney transplantation are mostly related to the 
ureteroneocystostomy, often requiring interventions with additional costs, morbidity 
and mortality. Our aim was to assess risk factors for urological complications in deceased 
donor kidney transplantation. 
Patients and Methods
Between January 2000 and December 2011, 566 kidney transplantations were performed 
with deceased donor kidneys. Recipients were divided in a group with, and a group 
without urological complications, defined as the need for a percutaneous nephrostomy 
catheter or surgical revision of the ureteroneocystostomy. Univariate and multivariate 
analyses were performed. 
Results
Univariate analysis showed increased number of male donors (p=0.041), male recipients 
(p=0.002), pre-emptively transplanted recipients (p=0.007), and arterial reconstructions 
(p=0.004) in the group with urological complications. Less urological complications 
occurred in recipients on hemodialysis (p=0.005). More overall surgical interventions 
(p<0.001), surgical site infections (p=0.042), urinary tract infections (p<0.001) and 
lymphoceles (p<0.001) occurred in the group with urological complications. Multivariate 
analysis showed that male recipients (p=0.010) and arterial reconstructions (p=0.019) 
were independent risk factors. No difference was found between both groups in patient 
or graft survival. 
Conclusion 
Recipient male gender and arterial reconstruction are independent risk factors for 
urological complications after deceased donor kidney transplantation. Nevertheless, 
graft and recipient survival is not different between both groups.
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INTRODUCTION
Urological complications after kidney transplantation are reported to occur between 
2.5% and 30% of all recipients.1-5 Major urological complications, for example leakage 
and stenosis, are often related to the ureteroneocystostomy.6-10  In most cases these 
complications require placement of a percutaneous nephrostomy (PCN). Sometimes, 
even a surgical revision is required, leading to additional morbidity and costs.3, 8, 11
Risk factors that contribute to the prevalence of urological complications need to be 
determined. So far, many factors have been described in literature, including several 
donor and recipient characteristics.1, 12 Furthermore, problems encountered during 
graft recovery, prolonged ischemia times, type of ureteroneocystostomy, presence 
of accessory arteries or stent placement might be of influence on the incidence of 
urological complications.1, 9, 11, 13
Due to the increasing number of patients with end-stage kidney disease and a continuing 
shortage of donors, the demand for kidney grafts led to extension of donor criteria 
by the Dutch Transplant Foundation. Alongside the Donation after Brain Death (DBD) 
donors, Donation after Circulatory Death (DCD) (category III) donors have been deemed 
eligible for transplantation.6, 14-16 A higher percentage of urological complications after 
deceased kidney donation has been reported, when compared to live donor kidney 
transplantation.8, 11 We aimed to assess the incidence of urological complications after 
kidney transplantation with grafts from DBD and DCD donors and identify independent 
factors associated with the development of these complications, in a multivariate 
analysis.
PATIENTS AND METHODS
The Erasmus MC, University Medical Center internal review board issued a formal written 
waiver for the need of ethics approval and the need for written informed consent. 
Between January 2000 and December 2011, all kidney transplantations performed with 
grafts from DBD and DCD (category III) donors at the Erasmus University Medical Center 
Rotterdam, were reviewed retrospectively. A total of 566 recipients were identified. The 
surgical reports and electronic patient system were screened for donor and recipient 
characteristics, and urological complications. Recipients were divided in two groups, 
one group with and one group without urological complications within 3 months’ time 
after transplantation. A urological complication was defined as any event leading to 
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the placement of a PCN or surgical revision of the ureteroneocystostomy during follow-
up. We argued that a PCN placement is the best possible parameter to identify those 
patients who had an adverse urological outcome. An increasing serum creatinine level 
combined with hydronephrosis on ultrasonography was reason for a PCN placement. 
Monitoring of the PCN position and imaging of the ureter is performed by an antegrade 
pyelography (APG). If leakage of the ureteroneocystostomy is diagnosed with an APG, 
both PCN and urinary bladder catheter are placed until the leakage stops. In case the 
leakage is diagnosed shortly after transplantation immediate surgical reconstruction 
is performed. If a total obstruction of the ureter is diagnosed with an APG, surgical 
intervention is inevitable. If the APG shows a stenosed ureter but contrast reaches the 
bladder radiological dilation of the ureter is performed. Afterwards a percutaneous 
nephrocystostomy catheter (PCNC) is placed for 2 weeks. If the stenosis persists a 
surgical ureter reconstruction is indicated and will be performed by a transplant 
surgeon, together with an urologist. 
Overall complications
Tacrolimus toxicity (>15µg/l), suspected acute tubulus necrosis (ATN), treatment for 
rejection (methylprednisolone and/or ATG), lymphoceles, surgical site infections and 
urinary tract infections were scored during the first 3 months after transplantation. 
Besides ureteral revisions, all other re-interventions were documented: re-interventions 
because of re-bleeding, lymphocele drainage, transplantectomy and re-exploration 
because of vascular complications. Graft failure was defined as primary non-function or 
loss of function requiring dialysis. All recipients had a follow-up of at least one year in 
our center.
Surgical technique
All transplantations were performed by a transplant surgeon or vascular surgeon and 
transplants were engrafted extraperitoneally in the iliac fossa. In presence of multiple 
renal arteries (in majority of cases two arteries) a reconstruction was performed on 
the bench. Dependent on the length of the artery an end-to-side or an side-to-side 
anastomosis was created. Urinary continuity was established by either an intravesical17 
(Politano-Leadbetter) or extravesical18 (Lich-Gregoir) ureteroneocystostomy. Intravesical 
anastomoses were created by performing a cystotomy on the anterior side to visualize 
the interior of the bladder and expose the trigone. A second (smaller) cystostomy was 
performed to create a new ureteric orifice. The ureter of the transplanted kidney as 
tunneled submucosally for approximately 2 centimeters. The distal end was trimmed, 
spatulated anteriorly at an optimal length to ensure a tension-free anastomosis and 
sutured to the bladder mucosa with 5-6 interrupted absorbable stitches. The cystotomy 
was then closed with a running suture. Extravesical anastomoses were created by 
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performing a 1-2 centimeter cystotomy on the anterolateral surface of the bladder dome 
to expose the mucosa of the bladder wall. A small incision was made in the mucosa. The 
transplant ureter was trimmed and spatulated posteriorly. The mucosa of the bladder 
was sutured to the ureteral end with a running absorbable suture. The detrusor muscle 
was closed over the anastomosis using one or two interrupted absorbable sutures 
to create a submucosal tunnel with an anti-reflux mechanism. Placement of a stent 
depended on pre-transplant urinary production, so that urinary production of the 
transplanted kidney can be determined. Stents were externalized suprapubicly with the 
tip positioned in the pelvis of the graft and removed after 10 days.
Postoperative medical care
Postoperatively, immunosuppressive therapy consisted of prednisolone (50mg a day), 
tacrolimus (dose was titrated based on serum value) and mycophenolate mofetil 
(1000mg twice a day). Basiliximab was used as induction therapy. Prednisolone was 
tapered and discontinued 4 months after transplantation. A prophylactic dose of 
480mg cotrimoxazole per day was given to prevent urinary tract infections. Cefazoline 
was given perioperatively. Standard dose of 12.000U heparin daily was given during 
the first 5 post-operative day. Valganciclovir treatment was given to patients at risk 
for CMV infection or reactivation. Initial episodes of acute rejection were treated with 
methylprednisolone, 1000mg a day for 3 days, ATG was given on indication.
Statistical analyses
Statistical analysis was performed using IBM SPSS version 20.0 (IBM Corp., Armonk, 
NY, USA). Variables studied are presented in Table 1 and Table 2. Categorical variables 
are presented as number (percentage) and were compared using the Chi-square test. 
Continuous variables are presented as mean with standard deviation (SD) and were 
compared using an independent sample T-test. We calculated odds ratios (OR) with 95% 
confidence intervals (CI), using a univariate and multivariate generalized linear model 
to identify independent risk factors for urological complications. All variables with a 
p-value <0.10 in the univariate analysis were included in the multivariate analysis. A 
p-value of <0.05 in our multivariate model was considered statistically significant. Graft 
and patient survival were analyzed using a Kaplan-Meier curve for survival distribution 
and compared using a log-rank test. 
Ethics
The manuscript is conducted in accordance to the principles expressed in the Declaration 
of Helsinki. Approval of our local ethics committee was not required for this study. 
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RESULTS
Baseline characteristics
Between January 2000 and December 2011, 566 kidney transplantations were performed 
with grafts from both DBD and DCD donors. An overview of the baseline characteristics 
is shown in Table 1. Urological complications were significantly more frequent in male 
donors, male recipients, pre-emptive transplantations and arterial reconstructions. 
Significantly less recipients on hemodialysis developed a urological complication. The 
number of kidney grafts from DBD and DCD donors was equally distributed in the group 
with and without urological complications.
Table 1 Baseline characteristics of the donors, recipients and grafts (n=566)
Total group
(n = 566)
No urological 
complication  
(n = 448)
With urological 
complication 
(n = 118)
p-value*
Donors
Male gender (%) 293 (51.8) 222 (49.6) 71 (60.2) 0.041
Age (mean) (SD) 50.48 (14.45) 50.35 (14.28) 51.01 (15.12) 0.661
DBD (%) 352 (62.0) 279 (62.3) 73 (61.9) 0.934
Recipients
Male gender (%) 351 (62.0) 263 (58.7) 88 (74.6) 0.002
Age (mean) (SD) 52.96 (13.95) 52.70 (13.77) 53.98 (14.65) 0.376
Multiple transplantations (%) 137 (24.2) 108 (24.1) 29 (24.6) 0.916
Diabetes Mellitus (%) 130 (23.0) 105 (23.4) 25 (21.2) 0.651
Pre-emptive transplantation (%) 20 (3.5) 11 (2.5) 9 (7.6) 0.007
Hemodialysis (%) 383 (67.7) 316 (70.5) 67 (56.8) 0.005
BMI (SD) 25.75 (5.03)
(n=516)
25.87 (5.11) 
(n=405)
25.33 (4.75) 
(n=111)
0.322
Grafts
Warm ischemic time (mean in minutes) (SD) 38.67 (18.72) 38.76 (19.42) 38.36 (15.89) 0.837
Cold ischemic time (mean in minutes) (SD) 1083.42 (350.59) 1083.57 (349.37) 1082.84 (356.73) 0.984
Arterial reconstruction (%) 70 (12.4) 46 (10.3) 24 (20.3) 0.004
Extravesical ureteroneocystostomy (%) 124 (21.9) 98 (22.1) 26 (22.4) 0.946
Stent placement (%) 273 (48.2) 213 (47.7) 60 (51.3) 0.484
*: p-value is provided between the group without urological complications and the group with urological 
complications 
SD: Standard Deviation; DBD: Donation after Brain Death; BMI: Body Mass Index
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Urological complications
Of the total 566 recipients, 117 received a PCN. In 15 recipients a PCN was placed because 
of leakage and in 102 because of hydronephrosis on ultrasonography. An endoscopic 
dilatation of the ureter was performed in 4 recipients, in 3 patients successfully and in 
1 recipient an additional surgical revision was required afterwards. A surgical ureteral 
revision was required in 31 recipients who previously received a PCN and in one recipient 
a surgical ureteral revision was required without a prior PCN placement based on 
leakage of the ureter shortly after transplantation. Choice of re-implantation was in 30 
cases a new ureterovesicostomy, in one patient a pyelovesicostmy and in one a ureter-
ureterostomy. Mean graft survival of the group with a surgical ureter reconstruction was 
5.57 years (inter quartile range of 2.14-9.27). In 83 recipients, the PCN could be removed 
without additional intervention.
Overall complications
Comparisons of the overall complications according to absence or presence of 
urological complications are presented in Table 2. There were significantly more overall 
surgical interventions, surgical site infections, urinary tract infections and lymphoceles 
in the group of recipients with urological complications. Primary non-function prevailed 
significantly less frequently in recipients with urological complications. 
Table 2 Overall complications
Total Group
(n = 566)
No urological 
complication  
(n = 448)
With urological 
complication 
(n = 118)
p-value*
Overall surgical intervention (%) 132 (23.3) 85 (19.0) 47 (39.8) <0.001
ATN (%) 240 (42.4) 187 (41.7) 53 (44.9) 0.535
Tacrolimus toxicity (>15µg/l) (%) 63 (11.1) 47 (10.5) 16 (13.6) 0.346
Surgical site infection (%) 50 (8.8) 34 (7.6) 16 (13.6) 0.042
Urinary tract infection (%) 130 (23.0) 84 (18.8) 46 (39.0) <0.001
Lymphocele (%) 17 (3.0) 3 (0.7) 14 (11.9) <0.001
Rejection treatment (%) 71 (12.5) 54 (12.0) 17 (14.4) 0.492
Primary non-function (%) 51 (9.0) 46 (10.3) 5 (4.2) 0.042
*: p-value is provided between the group without urological complications and the group with urological 
complications
PCN: Percutaneous Nephrostomy; ATN: Acute Tubulus Necrosis
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Multivariate analysis
All odds ratios regarding urological complications using univariate and multivariate 
analysis were presented in Table 3. Five factors (donor gender, recipient gender, 
pre-emptive transplantation, hemodialysis, arterial reconstruction) implemented in 
our univariate analysis showed a significant influence on the presence of urological 
complications and were therefore analyzed in a multivariate model. Recipient gender 
and arterial reconstruction were identified as independent risk factors in our multivariate 
analysis.
Donor type and urological complications
In total 118 (20.8%) recipients developed a urological complication and 5.7% of all 
recipients (32 out of 566) underwent a surgical ureteral revision. Of all recipients who 
developed a urological complication, 73 had a DBD donor graft and 45 a DCD. Table 4 
shows that DBD and DCD transplantations were not different regarding prevalence of 
urological complications. However, there were significantly more surgical site infections 
in the DCD group. 
Follow-up
Mean graft survival time was 4.02 years with a standard deviation of 3.47. Minimum 
graft survival was 0 day due to primary non function and maximum was 12.1 years. 
Mean patient survival was 5.13 years. Death censored graft survival regarding urological 
complications was presented by a Kaplan-Meier curve (Figure 1). No significant difference 
occurred in graft survival between the group with or without urological complications 
(p=0.707).
Table 3 Results of the multivariate analysis regarding urological complications
Univariate 
OR (95% CI)
p-value* Multivariate
OR (95% CI)
p-value*
Donors
Male gender 1.57 (1.02-2.33) 0.041 1.46 (0.96-2.24) 0.080
Recipients
Male gender 2.06 (1.32-3.29) 0.002 1.84 (1.15-2.93) 0.010
Pre-emptive transplantation 3.28 (1.29-8.12) 0.007 2.20 (0.82-5.81) 0.111
Hemodialysis 0.55 (0.36-0.83) 0.005 0.66 (0.42-1.04) 0.073
Grafts
Arterial reconstruction 2.23 (1.28-3.81) 0.004 1.96 (1.10-3.40) 0.019
*: p-value is provided between the group without urological complications and the group with urological 
complications
OR: Odds Ratio; CI: Confidence Interval
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Table 4 Characteristics and complications of the recipients with urological complications
Total 
(n=118)
DBD 
(n=73)
DCD
(n=45)
p-value*
Ureteral reconstruction (%) 32 (27.1) 24 (32.9) 8 (17.8) 0.130
Male gender recipient (%) 88 (74.6) 54 (74.0) 34 (75.6) 0.848
Male gender donor (%) 71 (60.2) 41 (56.2) 30 (66.7) 0.258
Arterial reconstruction (%) 24 (20.3) 16 (21.9) 8 (17.8) 0.587
Urinary tract infection (%) 46 (39.0) 28 (38.4) 18 (40.0) 0.859
Surgical site infection (%) 16 (13.6) 6 (8.2) 10 (22.2) 0.031
Lymphocele (%) 14 (11.9) 9 (12.3) 5 (11.1) 0.843
*: p-value is provided between the DBD and DCD group
DBD: Donation after Brain Death; DCD: Donation after Circulatory Death;  
PCN: Percutaneous Nephrostomy
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Figure 1 Kaplan-Meier survival, the black line corresponds to the group with urological complications and 
the grey line corresponds to the group without urological complications. This curve is censored for death. 
No significant difference occurred between both groups (p=0.707).
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DISCUSSION
In our study, 20.8% of all recipients of a kidney graft from a deceased donor had a 
urological complication as defined by PCN placement or surgical ureteral revision. As 
PCN placement is considered as a minimally invasive event in our center, the threshold 
to use a PCN is low, either for therapy, or for diagnosis. Eventually, only 32 recipients 
(5.7%) underwent a surgical ureteral revision for leakage or stenosis and graft survival 
was not worse in the population with urological complications.
It has been suggested that urological complications are caused by an insufficient blood 
supply to the ureter. Excessive dissection of the site known as ‘golden triangle’ (the site 
confined by ureter, kidney and renal artery) should therefore be avoided during graft 
recovery. Damage of this triangle might lead to necrosis of the distal ureter in 70% of 
the cases.4, 10, 11
Potential risk factors for urological complications including age, prolonged cold 
ischemia and recipient Diabetes Mellitus were reported not to play an important role 
in the occurrence of urological complications.1, 11 These findings are supported by our 
data (Table 1). In our study more urological complications occurred in male donors, 
male recipients and pre-emptive transplantations. The reason why male recipients 
may develop more urological complications is not exactly clear. An anatomical cause 
due to the presence of the funiculus that crosses the ureter might be an explanation, 
considering the ligamentum rotundum is ligated in females during the implantation. 
Furthermore, arterial reconstruction of the donor graft was highly associated with the 
prevalence of urological complications (Table 1), which is confirmed in the literature.19-21 
Relative ischemia of the ureter by an insufficient arterial blood supply is suggested to be 
the cause for leakage and stenosis. Malperfusion of accessory arteries may result from 
a small anastomosis with flow-limitation, greater turbulence or more vulnerability for 
traction injury. 
There is growing evidence on the superiority of the extravesical ureteroneocystostomy 
when compared with the intravesical technique, with or without additional routine 
stent placement.2, 9, 13, 22-24 In our population, the type of ureteroneocystostomy was 
depended on surgeons’ preference and stent placement on residual urinary production. 
Both, type of ureteroneocystostomy and the presence of a stent could not be defined as 
a risk factor in our analysis (Table 1). However, there were significantly more surgical site 
infections, urinary tract infections, lymphoceles and surgical re-explorations because of 
hemorrhage, transplantectomies or vascular complications (Table 2), in the group with 
urological complications. 
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Although the mean graft survival of DCD donors is suspected to be shorter than that of 
DBD donors, there are no studies on the occurrence of urological complications in those 
groups. Therefore, the finding that grafts from a DBD donor were not superior to DCD 
donor grafts with respect to urological complications (Table 4) is an important finding. In 
addition, our Kaplan Meier survival analysis (Figure 1) demonstrates no difference in long 
term graft survival between the populations with and without urological complications 
which is supported by other studies.2, 8, 11  It should however be kept in mind that the 
population with urological complications is a selection with a functioning graft. 
Another important finding in our study was the fact that primary non-function of 
the graft or graft loss within 3 months was significantly lower in the group without 
urological complications (Table 2). This probably is a bias since urological complications 
like leakage and hydronephrosis by a stenosis at the ureteroneocystostomy junction site 
cannot be detected in a non-functioning graft. Furthermore, recipients transplanted pre-
emptively, had a significantly higher risk to develop urological complications. There is no 
clear explanation for this finding. However, this subgroup consists of only 20 recipients, 
which might have biased the statistical outcome. One other limitation of our study is 
the fact that some potential risk factors, such as donor BMI, ureteral vascularization or 
length of the ureter could not be documented prospectively. Despite the retrospective 
character of our study and its disadvantages, we describe the most detailed group 
regarding urological complications of kidney graft recipients from a deceased donor so 
far as known from the literature.
Based on our study of kidney transplantations from a deceased donor, we conclude that 
recipient’s gender and arterial reconstruction are independent risk factors to develop 
a urological complication. However, donor type (DBD and DCD), primary non-function, 
type of anastomosis, and the presence of multiple transplantations could not be defined 
as risk factor in our univariate and multivariate analyses. This means that donor type and 
surgical anastomosis technique are less important factors for the urological outcome, 
which is in contrast to what one might argue.
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ABSTRACT
Introduction 
Major urological complications after kidney transplantation include leakage and 
stenosis of the ureter. Treatment by PCN placement, radiological dilatation or surgical 
reconstruction is associated with morbidity, risks and costs. We present clinical outcome 
and a cost analysis of patients with urological complications after kidney transplantation.
Patients and Methods
In a retrospective single center study, kidney transplantations that were performed 
between January 2007 and January 2012 from both deceased donors and living donors 
were analyzed. The hospital electronic patient system and surgical charts were reviewed 
for urological complications. Based on real prices, direct medical costs of urological 
complications were determined until one year after kidney transplantation.
Results 
Out of 809 patients that underwent kidney transplantation, 188 recipients (23.4%) 
required PCN placement, 146 due to hydronephrosis and 42 due to leakage. In 47 
recipients (5.8%) additional radiological and/ or surgical intervention was required. There 
was no graft loss caused by the radiological or surgical ureter re-intervention and graft 
survival between patients with or without urological complications was comparable. The 
total direct medical costs made for urological complications after kidney transplantation 
were on average € 2.322 per patient. 
Conclusion 
Urological complications after kidney transplantation may lead to an increase of costs 
up to € 2.322; however, these costs can be legitimized as the occurrence of urological 
complications does not influence graft survival. 
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INTRODUCTION
Kidney transplantation is the gold standard for patients with end stage kidney disease. 
Compared to dialysis, transplantation is advantageous for patient life expectancy, quality 
of life and it decreases medical costs.1-3 While the total number of deceased donor kidney 
transplants remains stable, the incidence of live donor kidney transplantation increases 
considerably worldwide with superior graft survival.4 However, during the initial years of 
live donor kidney transplantation, a higher rate of urological complications was found 
compared to deceased donor kidney transplantations. Nowadays, no difference in 
urological complications is reported between those two groups.5-8 
Urological complications account for a significant cause of morbidity after kidney 
transplantation. The incidence is between 0.5% and 30%, depending on patient 
selection, definition of urological complications and follow-up.6, 9-11 Deterioration of 
renal function is often the first sign of a major urological complication, for example, 
ureteral leakage or obstruction, and requires placement of a percutaneous nephrostomy 
(PCN).12 In case of leakage or obstruction, radiological or surgical ureter reconstruction 
is required in up to 10% of these patients.6, 13-16 The most important factors that might 
influence the urological outcome are the type of donor nephrectomy, type of organ 
preservation, vascular reconstruction of the renal artery17-19 and ureteral implantation 
technique.7, 10, 20, 21 Urological complications cause significant morbidity in recipients of 
a kidney transplant. Besides the inconvenience related to radiological and surgical re-
interventions for urological complications are associated with increased medical costs.
Our aim was to illustrate the clinical outcome of patients with urological complications 
and to perform a cost analysis of urological complications after kidney transplantation. 
PATIENTS AND METHODS
Data from our electronic patient system were analyzed to identify all patients with 
a kidney transplant performed between January 2007 and January 2012. Using a 
prospective database, donor and recipient characteristics, as well as data on radiological 
and surgical re-interventions related to urological complications, were collected. Patients 
were divided into two groups, discriminating those without urological complications 
from those with urological complications. A urological complication was defined as the 
need for a PCN placement or surgical ureter revision following transplantation within 
3 months after transplantation. We argued that a PCN is the best parameter to identify 
patients with an adverse urological outcome. In a sub-analysis we studied the incidence 
of urological complications in deceased and living donor kidney transplantation. 
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Kidney transplantation
Well-trained transplant surgeons performed all kidney transplantations. After 
extraperitoneal graft placement in the iliac fossa, continuity of the urinary tract 
was established by an ureteroneocystostomy (either a Politano-Leadbetter22 or a 
Lich-Gregoir23). In those cases where the surgeon preferred stenting of the ureteral 
anastomosis, an 8 French stent was introduced into the donor ureter via the bladder 
and the stent was externalized suprapubically. Post-operative immunosuppression 
consisted of prednisolone (starting with 50mg a day), tacrolimus (dose was titrated 
based on serum value) and mycofenolate mofetil (2 times a day 1000mg). Baxiliximab 
was used as induction therapy. Prednisolone was tapered and discontinued within 4 
months after transplantation. Until 4 months after transplantation, a prophylactic dose 
of cotrimoxazole (480mg a day) was given to prevent PCP infections and urinary tract 
infections. Valganciclovir treatment was given to patients at risk for CMV infection or 
reactivation. Episodes of acute rejection were treated with methylprednisolone, 1000mg 
a day for 3 days, ATG was given on indication. 
Assessment of urological complications
During the early post-transplant period, daily monitoring of serum creatinine and 
urinary production was performed. When urine leakage occurred within 2 days after 
transplantation, immediate surgical ureter reconstruction was performed. Anastomotic 
ureter disruption was suspected when the patient complained of pain in the fossa, 
urinary production decreased, serum creatinine increased or in case of urine leakage via 
the wound. Obstruction of the ureter was suspected when serum creatinine increased. 
A routine ultrasonography of the graft was performed on day 1, and was repeated in the 
post transplantation period when obstruction or fluid collections were expected (Figure 
1). In case of hydronephrosis, a PCN was inserted and an antegrade pyelography was 
performed. In case of leakage both a PCN and a urinary catheter were inserted. In case of 
hydronephrosis, the effect of the PCN was monitored by serum creatinine, when the serum 
creatinine did not show a decrease or even demonstrated an increase, hydronephrosis 
unlikely to be the cause for the deteriorated of kidney function. In that case, the PCN was 
removed and a kidney biopsy was performed. When the antegrade pyelography showed 
a complete stenosis of the anastomosis between the ureter and bladder, a surgical 
reconstruction was planned. When the antegrade pyelography showed a subtotal ureter 
stenosis with contrast passage into the bladder, the PCN was temporarily closed to await 
the effect on serum creatinine. When serum creatinine did not rise, the PCN was removed. 
When serum creatinine increased after closing the PCN it was reopened and further 
therapy was initiated. For a ureter stenosis with a maximum length of 1 centimeter, a 
radiological dilation of the ureter was performed. After dilatation, the PCN was placed 
through the ureter into the bladder. After two weeks, an antegrade pyelography was 
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repeated and when the relative stenosis persisted and serum creatinine increased after 
closing the PCN the radiological dilatation was repeated. When repetitive radiological 
dilatations remained unsuccessful, a surgical reconstruction of the anastomosis was 
performed. The technique of ureter reconstruction depended on findings during the 
operation, including degree of fibrosis, length of the ureteral stricture, aspect of the 
ureter and mobility of the bladder. All interventions were discussed in a multidisciplinary 
team meeting with the transplant surgeons, nephrologists, radiologists and urologists. 
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Figure 1  Flow-chart of assessing the urological complications.
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Cost analysis
The direct medical costs due to urological complications after kidney transplantation 
were calculated combining data from the patient registry with in hospital costs. First, the 
total number of ultrasonographies, PCN placements, PCN replacements (or substitutions), 
antegrade pyelographies, radiological dilatation and surgical reconstructions of the 
ureter were collected and noted for each recipient. Hospital readmission because of 
urological complications (urinary tract infection, sepsis, PCN obstruction or dislocation) 
and hospital stay for radiological and surgical re-interventions were noted. Secondly, an 
independent financial advisor of the Erasmus MC, University Medical Center, provided 
the prices for all direct medical costs determined on real prices. Furthermore, costs were 
estimated by multiplying resource utilization with the cost per unit of resource (i.e., full 
costing in accordance with Dutch guidelines24 for economic evaluations in health care). 
Finally, we determined the mean total direct medical costs per patient for urological 
complications after kidney transplantation. Costs were calculated in Euros (€). The base 
year for all costs was 2012; costs made in other years were converted to 2012 euros 
using the general price index. Costs of organ procurement were excluded because of 
the difference between deceased and living donation (incorporated by an independent 
organ procurement organization (Euro-transplant) or by the hospital). Costs of the 
kidney transplantation (including admission and non-urological complications, e.g. 
rejection) were not taken into account, since these should be equally distributed 
within these two groups. Costs made for rejection (radiological procedures, biopsies, 
medication and hospital admission) or costs related to primary non-function (dialysis, 
medication, admission, and transplant nephrectomy) were also not included. Overhead 
and housing were also excluded.
Statistical analysis
Statistical analysis was performed using IBM SPSS version 20.0 (IBM Corp., Armonk, NY, 
USA). Categorical variables are presented as number (percentage) and were compared 
using the Chi-square test. Continuous variables are presented as mean with standard 
deviation (SD) and were compared using an independent sample T-test. A p-value <0.05 
was considered statistically significant.
RESULTS
Baseline characteristics of the 809 kidney transplant recipients (252 deceased donors and 
557 living donors), transplanted between January 2007 and January 2012 are presented 
in table 1. In total 190 patients (23.4%) had a urological complication as defined by 
PCN insertion or surgical reconstruction of the ureter. The mean age of donors in the 
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group with urological complications was significantly higher (p<0.001) compared to the 
group without urological complications. In addition there were significantly more male 
recipients (p<0.001) and recipients of a living donor kidney transplantation (p=0.029) in 
the group with urological complications. There were no significant differences in type 
of anastomosis (intravesical or extravesical) or in the prevalence of stent placement 
between the groups with and without PCN. At 1 year serum creatinine level was 
significantly higher but there was no difference in graft survival between the groups 
with and without urological complications (Table 1). Follow-up was performed until 
April 2013, with a mean of 36 months after transplantation (SD 20 months). Hospital 
stay of patients after living donor kidney transplantation was significantly shorter 
(p=0.022); also, graft survival after a living donor transplantation was significantly 
longer (p=0.004) compared to patients with a deceased donor graftIn the group with 
urological complications (190 ripients), 47 patien received an organ from a deceased 
donor and 143 from a living donor. No significant differences in the number of PCN 
placements, radiological ureter dilatations or surgical ureter reconstructions between 
recipients with a deceased or living donor kidney transplantation were found (Table 
2). Out of 809 kidney transplantations, 188 recipients (23.2%) required a PCN, 42 due 
to fluid collections or leakage, and 146 due to hydronephrosis on ultrasonography. 
In 18 of the 190 recipients (9,5%), a radiological percutaneous dilatation of the ureter 
was performed, in 3 patients due to stenosis after primary leakage and in 15 patients 
due to primary subtotal stenosis. Eight recipients of these 18, required an additional 
surgical ureter reconstruction after radiological ureter dilatation; all had hydronephrosis 
as primary diagnosis. This means that 10 patients had been treated successfully with a 
Table 1 Baseline characteristics (donor and recipient) of 809 kidney transplants in recipients with and 
without urological complications. A urological complication is defined as the need for a percutaneous 
nephrostomy or surgical ureter reconstruction within the first 3 months after kidney transplantation.
Without urological 
complications n=619
With urological 
complications n=190
p-value
Donor male sex(%) 289 (46.7) 82 (43.2) 0.393
Mean donor age (SD) 51.2 (12.96) 55.6 (13.04) <0.001
Living donor(%) 414 (66.9) 143 (75.3) 0.029
Recipient male sex(%) 390 (63.0) 146 (76.8) <0.001
Mean age KTx (SD) 51.6 (14.49) 51.3 (14.91) 0.797
Extravesical anastomosis (%) 207 (33.4) 61 (32.1) 0.732
Stent placement (%) 515 (83.2) 164 (86.3) 0.306
Functioning graft in months (SD) 35.3 (20.30) 38.33 (18.90) 0.062
Mean creatinine 1 year KTx (μmol/L) (SD) 131.5 (50.20) 159.4 (60.34) <0.001
SD: standard deviation, KTx: kidney transplantation
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radiological dilatation (1,2%). A total of 37 patients (4,6%) required a surgical ureteral 
reconstruction; 30 due to hydronephrosis and 5 after primary leakage followed by 
stenosis. In two patients (0,25%), a surgical reconstruction of the ureter anastomosis was 
performed within 2 days after transplantation due to leakage (Figure 2). In total, 5.8% 
of the recipients underwent radiological or surgical treatment because of urological 
complications.
 
8  
619 without 
urological 
complications 
15 radiological ureter 
dilatations 
2 direct surgical ureter 
reconstructions 
 
Ultrasonography 
showing hydronephrosis 
146 PCN placements 
109 conservative 
809 kidney transplantations 
2 leakages < 2days  
post-operatively 
3 radiological 
ureter dilatations 
Ultrasonography showing  
fluid collection/ leakage 
42 PCN placements 
30 surgical ureter reconstructions 5 surgical ureter  
reconstructions 
34 conservative 
Figure 2  Flow-chart of all kidney transplantations performed, showing prevalence and treatment of 
urological complications.
Table 2 Characteristics of the 190 recipients with a urological complication. Sub-analyses were based on 
deceased or living donor kidney transplantation. 
Deceased donor n=47 Living donor n=143 p-value
Percutaneous nephrostomy(%) 46 (97.9) 142 (99.3) 0.405
- Leakage(%) 7 (14.9) 37 (25.9) 0.122
- Hydronephrosis(%) 40 (85.1) 106 (74.1) 0.122
Radiological ureter dilatation(%) 4 (8.5) 14 (9.8) 0.795
Surgical ureter reconstruction(%) 11 (23.4) 26 (18.2) 0.433
Functioning graft in months (SD) 36.9 (20.88) 38.8 (18.26) 0.557
SD: standard deviation
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Characteristics of the 47 recipients who requed a radiological or rgical ureter intervention 
are presented in table 3. In this subgroup, no significant differences were found in 
technique of ureteroneocystostomy (p=0.281) or prevalence of stent placement 
(p=0.796) between the deceased and living donor kidney transplantation groups. In 
patients that underwent a surgical reconstruction of the ureteroneocystostomy, urinary 
continuity was established in 30 patients (81.1%) by re-implantation of the transplant 
ureter onto the bladder. In 2 patients (5.4%), the transplant pelvis was connected directly 
to the bladder. In the remaining 5 patients (13.5%), other reconstruction techniques 
were used; in 3 patients the native ureter was used, one patient had a reconstruction 
with the use of the Boari technique and in one patient a reconstruction was not possible 
because of complete fibrosis of the ureter and the pelvic system. This patient remained 
PCN dependent.
The total direct medical costs related to urological complications after kidney 
transplantation were €2.322 on average per patient (Table 4). In more detail, in 694 
patients (85.8%) one or more additional ultrasonography(ies) were performed to 
evaluate transplant function or to verify PCN position. A total of 1948 ultrasonographies 
were performed accounting for €158.353. In 188 patients (23.2%), 275 PCN insertions 
were performed accounting for €91.418. In 102 patients (12.6%), 295 PCNs were replaced 
accounting for €59.891. A total of 331 antegrade pyelographies were performed in 167 
patients (20.6%) accounting for €48.965. Radiological ureter dilatation was performed 
22 times in 18 patients (2.2%); costs were €15.313. Surgical ureteral reconstruction was 
performed 41 times in 37 patients (4.6%). Total costs for the surgical reconstruction were 
€82.030. One hundred forty seven patients (18.2%) were hospitalized with urological 
Table 3 Characteristics of the 47 recipients with radiological ureter dilatation or surgical ureter 
reconstruction.
Deceased  n=14 Living n=33 p-value
Extravesical anastomosis of KTx(%) 4 (28.6) 15 (45.5) 0.281
Stent placement during KTx(%) 11 (78.6) 27 (81.8) 0.796
Radiological ureter dilatation(%) 4 (28.6) 14 (42.4) 0.372
Surgical ureter reconstruction type(%) 11 (78.6) 26 (78.8) 0.987
-Ureteroneocystostomy(%) 7 (50.0) 23 (69.7) 0.199
-Pyelocystostomy(%) 0 (0.0) 2 (6.1) 0.347
-Other*(%) 4 (28.6) 1 (3) 0.009
Functioning graft in months (SD) 39.6 (23.08) 37.9 (17.16) 0.785
KTx: kidney transplantation, SD: Standard Deviation; %: percentages; *3 with native ureter, 1 Boari 
technique, 1 reconstruction was not possible
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complications (urinary tract infection, urosepsis, PCN obstruction of dislocation). They 
were in the hospital for 2382 days with a total cost of €1.131.045. Total hospital stay for 
patients that underwent a surgical ureteral reconstruction was 614 days for 31 patients 
(3.8%). The other 6 patients had a ureter reconstruction during the initial admission for 
the transplant. Costs on hospital admission related to the ureter reconstruction were 
€ 291.546. Total costs incurred for the interventions were € 455.970 and for the admission 
days € 1.422.591. This equates € 2.322 per patient. 
DISCUSSION
In this retrospective single-center study, we present the incidence of urological 
complications in a cohort of 809 kidney transplantations performed between January 
2007 and January 2012. Significantly more urological complications occurred in patients 
with an older donor (p<0.001), a living donor (p=0.029) and in male recipients (p<0.001). 
Importantly, no grafts were lost due to the need of supplementary radiological or 
surgical interventions. A number of issues related to these findings should be discussed. 
The surgical approach of kidney procurement in living donor nephrectomy is totally 
different from decreased donor nephrectomy. An excessive dissection of peri-ureteral 
tissue or tension on the ureter during living donor nephrectomy could be an explanation 
for the higher number of urological complications in these recipients.10, 11, 25  Trauma 
during donor nephrectomy might be the reason for ureter edema causing functional 
hydronephrosis that resolves spontaneously without treatment. This might explain 
the difference between 23.2% of patients requiring a PCN and 5.8% that actually 
Table 4 An overview of direct medical costs of interventions related to urological complications after 
kidney transplantation.
Recipients
n=809
Sumof all 
interventions
Intervention 
costs
Total costs
Ultrasonography 694 (85.8%) 1948 € 81 € 158.353
PCN placement 188 (23.2%) 275 € 332 € 91.418
PCN replacement 102 (12.6%) 295 € 203 € 59.891
APG 167 (20.6%) 331 € 148 € 48.965
Radiological ureteral dilatation 18 (2.2%) 22 € 696 € 15.313
Surgical ureteral reconstruction 37 (4.6%) 41 € 2001 € 82.030
Hospitality days of re-admission 147 (18.2%) 2382 € 475 € 1.131.045
Hospitality days for ureteral reconstruction 31 (3.8%) 614 € 475 € 291.546
Total costs € 1.878.561
Average costs per patient € 2.322
PCN: Percutaneous Nephrostomy; APG: antegrade pyelography 
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required radiological or surgical intervention. The relatively high numbers of urological 
complications in male recipients could have an anatomical cause. The crossing 
funiculus might be an explanation for ureter obstruction in males, considering that the 
ligamentum rotundum is ligated during transplantation in females. Another explanation 
for the increased obstruction in males, is that they have a thicker bladder wall compared 
to women.26
Of the 809 kidney transplantations performed, 188 recipients (23.2%) required PCN 
placement, which is higher than reported in the literature.9 When graft function 
deteriorates, the threshold to use a PCN for the indication of dilated pyelum or ureter 
is low in our center. Alberts et al. report an incidence of 12.3% of PCN placement and 
a surgical reconstruction in 5.2%.9 In our population, 37 recipients (4.6%) (including 
2 recipients within two days) required a surgical ureter reconstruction after kidney 
transplantation, which is comparable to the literature.9, 10, 20 Although 1 year graft 
survival shows no difference between the group with PCN and the group without PCN, 
at 1 year, serum creatinine levels are significantly higher in the group with urological 
complications (Table 4). Although increased numbers of urological complications 
occurred in the living donor group, a sub-analysis of the group with a urological 
complication showed no differences in incidence of PCN placement when comparing 
transplantations from a deceased and living donors. As published before, no differences 
between DBD and DCD donors were found.27 
This study was performed in a high volume kidney transplant center. Although it is not 
common in the literature to appoint the number of PCN placements, this intervention 
is related to urological complications. The percentage of PCN placements is rather high 
in our center, but even a slight hydronephrosis leads to a PCN, even as a diagnostic 
tool. In the event that the PCN insertion did not lead to improvement of graft function, 
mechanical factors were unlikely to be the cause. The PCN was then removed, and a 
kidney biopsy was performed. 
Our study has some limitations. Firstly, a retrospective design was used, which might 
have caused some bias in data collection. Secondly, we were only able to capture direct 
medical costs during our cost analysis. Indirect costs (such as housing and overhead) 
and direct non-medical costs (as absence from work) were not included in our study. 
The consequence of the retrospective study design resulted in an estimated amount of 
cost, which is likely an underestimation. Total direct medical costs made for urological 
complications after kidney transplantation were € 2.322 per patient on average. 
Although, this is an underestimation of the total costs related to all complications after 
kidney transplantation (rejection and non-functioning of the graft were not included), 
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this study provides specific insights in costs related to ureteral complications after 
kidney transplantation.
Kidney transplantation has an economic benefit with a significant cost reduction 
as compared to dialysis.3, 28, 29 Urological complications after kidney transplantation 
are a major concern and associated with morbidity, decreased quality of life and 
additional costs. Despite the relatively large number of PCN placements after kidney 
transplantation in these series, only a small number of patients required a revision of 
the ureter anastomosis. Overall urological complications do not influence one year graft 
survival.  
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ABSTRACT
Introduction
To study the short- and long-term outcomes of kidney transplantation in patients 
with a bladder augmentation or urinary diversion compared to patients with a kidney 
transplantation in a normal functional bladder.
Patients and Methods
Between January 2000 and March 2011, 13 patients received 16 grafts into a reconstructed 
urinary tract. We performed a retrospective case-control study and matched each 
patient to 4 controls for donor and recipient gender and year of transplantation.
Results
Short- en long-term complications of kidney transplantation occurred in 12 patients, 
varying from urinary tract infections to medical hospitalization with or without surgical 
or radiological intervention. In 5 patients a percutaneous nephrostomy (PCN) was 
placed followed by surgical re-intervention. In three patients the grafts failed as a result 
of chronic rejection and were re-transplanted. There was no graft loss as a result of 
surgical complications or the reconstructed urinary tract. One-year patient and graft 
survival was 100%. After five years all patients were alive and seven of nine grafts (77.8%) 
were functioning. Mean follow up time was 4.3 years. Among the controls, 55 grafts 
were transplanted in 52 patients. Ten patients received a PCN. Five patients needed 
surgical re-intervention. In three patients transplantectomy was performed for ongoing 
rejection. Three patients were re-transplanted. One patient had a failing graft 7.5 years 
post transplantation and became dialysis dependent.
Conclusion
Kidney transplantation in patients with a reconstructed urinary tract has an increased 
complication rate. Nevertheless, the long-term results are comparable to patients with 
a normal urinary bladder.
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INTRODUCTION
In the past, patients with untreatable lower urinary tract disease have been excluded 
from kidney transplantation, because it was thought that the bladder that contributed 
to the destruction of the native kidneys would threaten a kidney allograft.1, 2 Complex 
urinary reconstructive procedures like bladder augmentation, Bricker3, Indiana Pouch4 
and Mitrofanoff5 are increasingly used due to advanced possibilities and kidney 
transplantation is nowadays offered to individuals without a functional bladder.1, 6
The first successful kidney transplantation connected to an augmented bladder was 
performed and reported by Kelly6, twelve years after the first kidney transplantation. 
There is controversy about the safety of kidney transplantation for patients with a 
reconstructed urinary tract, due to the risk of complications potentially leading to graft 
loss. For the small group of kidney transplantation recipients with urinary diversion 
a higher incidence of surgical complications, wound healing problems and urinary 
tract infections, are reported.7-9 However, long-term graft and patient survival seem to 
be similar to results of kidney transplantation for patients with a functionally innate 
bladder.7-11
Data in the literature about adult patients, with an augmented bladder in situ, receiving 
a kidney transplantation are scarce. Kidney transplantation in patients with a urinary 
conduit or reconstructed urinary diversion is reported to be 0,2% to 2,3% of the total 
number of procedures in single center studies.7-9 Thereby, most series are published 
before the surgical technique and immunosuppressive medication were well developed. 
In this manuscript, the short- and long-term results of adult patients who received a 
kidney transplantation connected to a reconstructed urinary tract in the Erasmus 
Medical Center from January 2000 until March 2011 will be presented.
PATIENTS AND METHODS
Study population and data selection
The hospital data-base showed a total of 1427 patients who have been identified as 
kidney transplantation recipients between January 2000 and March 2011. These patients 
were screened for having a reconstructed urinary tract at the time of transplantation, 
which resulted in thirteen suitable patients. Those thirteen patients were matched to 
four patients with an innate urinary bladder who underwent a kidney transplant. The 
criteria for the matching process were donor gender and the gender of the recipient, 
living or deceased donor, and year of the transplantation in order to have a comparable 
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follow-up time. All records were reviewed for functional outcome, surgical and medical 
complications.
All percutaneous nephrostomy drainages (PCN), surgical re-interventions, acute 
rejection episodes, urinary tract infections and graft- and patient survival were 
registered. Rejection was biopsy proven and urinary tract infection was defined positive 
if medication was administered. Graft survival was defined by a functioning kidney 
transplant without the need for dialysis or graft removal during follow up. Follow up 
was performed until August 2011 for all cases and controls.
Operative technique 
All kidney transplantations were performed by dedicated transplant surgeons whereas 
the anastomosis of the transplant ureter was performed by an experienced urologist. 
An extraperitoneal approach, using a half moon-shaped incision, preferably on the 
right side was performed. In case of contra-indications, like medical history with an 
urostoma or vascular abnormality, the kidney was engrafted in the left iliac fossa. 
Vascular connection of the artery and renal vein were performed end-to-side to the 
iliac vessels. The ureter was led to the reconstructed urinary tract without any kinking, 
spatulated distally and tension free anastomosed. Both intravesical and extravesical 
anastomosis were performed with resorbable sutures (PDS 5-0). Depending on the 
personal preference of the surgeon, a silicone stent (5 or 8-French) was used to relieve 
the new made anastomosis of the ureter.12, 13
In case of a Bricker and Indiana Pouch, described by Bricker3 and Rowland4 respectively, 
a ureter anastomosis was performed end-to-side to the terminal ileum or teniae 
of the caecum. The native bladder is left intact. In case of a Mitrofanoff5 or a trans-
appendicular continent conduit, in which a normal functional bladder is present, an 
intra- or extravesical ureter anastomosis was performed depending on the preference 
of the urologist. One patient (patient 11) had a bladder augmentation performed 
by pediatric surgeons with the native extended left ureter to avoid involvement of 
the intestine tract. Post operatively, immunosuppressive medication consisted of 
tacrolimus and methylprednisolon, and antibiotics (Co-trimoxazol) were provided to 
the patient. A PCN drain was placed in case of declining kidney function and signs 
of hydronephrosis on ultrasonography. The functioning of the PCN was checked by 
an antegrade pyelography (APG), visualizing the location of the PCN, a leakage or a 
stenosis. 
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Statistical analysis
Median and inter quartile ranges (IQR) are presented unless otherwise stated. Statistical 
analyses were performed by Mann-Whitney U and cross-tabs, using SPSS. Recipient and 
graft survival was analyzed by a Kaplan-Meier curve. Estimates between the case and 
control group were compared using the long rank test. 
RESULTS 
From a total of 1427 transplanted kidney grafts between January 2000 and March 2011, 
thirteen patients were transplanted with a reconstructed urinary tract in situ. Of those 
thirteen patients (Table 1 and 2), three received a re-transplantation and represent 1% of 
the total number of kidney transplantations. Ten patients had a living (un)related donor 
and three had a deceased donor, with a gender ratio (male:female) of 6:7. The median 
age of the recipients at the time of the renal transplantation was 23 years (IQR 20-45) 
(Table 2) with a gender ratio (male:female) of 8:5.
All reconstructed urinary tracts were performed with a median of 96 months (IQR 24 - 
138 months) prior to the transplantation. The median age of the recipients at the time of 
the bladder reconstruction was 22 years (IQR 12-30) (Table 2). Type of the reconstruction 
(with or without an augmentation) and indication for urinary deviation are lined out in 
table 1. Complications occurred in twelve patients, varying from minor complications 
like urinary tract infections to major complications which needed surgical intervention 
or medical hospitalization (Table 1). Nine patients (patients 1, 3, 4, 7, 8, 9, 10, 12 and 13) 
developed a urinary tract infection that was medically treated in a timeframe to three 
months postoperatively. Five patients (patients 2, 4, 6, 9 and 12) required a PCN drain 
placement, between three weeks and two months postoperatively. All of these patients 
underwent a surgical re-intervention.
Three of five patients that received a PCN had a ureter re-implantation. In two cases 
(patients 4 and 9) a new ureteral anastomosis was created and in one case (patient 
2) the graft pyelum was connected to the conduit. Patient 6 developed an avascular 
part of her Bricker which was revised two months after the transplantation and patient 
12 developed a seroma. Surgical re-interventions were performed at a median time 
frame of seven months post transplantation (between 2-52 months). Acute rejection 
episodes that were treated successfully by immune suppressive medication occurred 
in four patients (patients 3, 4, 7 and 10), all were biopsy proven. After four years patient 
4 required a surgical ureter revision but unfortunately dialysis was needed seven years 
post transplantation due to recurrent urinary tract infections. 
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Table 1 Clinical characteristics of the patients (n=13)
Patient 
no.
Sex Type  
conduit
Age  
conduit
Reason  
conduit
Age ktx 
(year)
L/ D 
donor
Type 
anast.
Percutaneous/ 
surgical  
re-intervention 
(year)
GS-1 GS-5 Failure
1 M IP 22 RN 23 (2002) L Extra - 1 1 -
2 M B 26 RN 39 (2002) L Extra PCN (2002) 
stenose; 
pyelolisostomy
1 0 August 
2003
41 (2004) L Extra Encrusted 
pyelitis (2009) 
PCN (2009), PNL 
(2009)
1 1 †
3 F IS 5 NB 20 (2002) L Intra - 1 1 March 
2010
28 (2010) L Extra PCN (2010) 1 - -
4 M B 25 NB 27 (2002) D ? PCN (2002) 
R U-B (2006)
1 1 November 
2009
5 F IP 46 RI 51 (2003) L Extra - 1 1 -
6 M B 45 RI 55 (2003) L ? PCN (2003)  
Revision Bricker 
(2003)
1 1 -
7 M M 9 RN 19 (2006) L Intra - 1 0 July 2008
22 (2009) L Extra PCN (2009) R 
U-B (2009)
1 - -
8 M B 26 RI 28 (2006) L Extra - 1 1 -
9 F IP 14 RI 20 (2007) L Extra PCN (2007) R 
U-B (2008)
1 - -
10 M M 19 NB 21 (2008) D ? - 1 - -
11 F EU 10 NB 16 (2009) D Extra - 1 - -
12 F M 15 NB 24 (2010) L Intra PCN (2010);  
lymfocele – 
seroom 
diagn laparosc 
+ mesh removal
1 - -
13 M B 56 TBC-C 64 (2011) L Extra - - - -
IP: Indiana Pouch, B: Bricker, M: Mitrofanoff, IS: Isolated Sigmoid, EU: Extended Ureter, 
RI: Recurrent Infections, NB: Neurogenic Bladder, RN: Reflux Nefropathie, TBC-C: Tuberculose Cystitis, 
L: Living, D: Deceased, PCN: Percutaneous Nephrodrain, R U-B: Revision Ureter-Bladder anastomosis, 
GS-1: Graft Survival 1 year, GS-5: Graft Survival 5 years, 0: non functional graft,  
1: functional graft, -: no follow-up yet, ktx: Kidney Transplantation, PNL: Percutaneous Nephrolithotomy, 
†: deceased, ?: unknown 
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Four patients (2, 3, 4 and 7) had graft failure as a result of chronic rejection after 
respectively one, eight, seven and two years. Three patients (2, 3, 7) were re-transplanted 
after respectively two, eight and three years and all those re-transplantations had a 
PCN placement due to hydronephrosis. In two cases a surgical intervention followed. 
One patient (2) had long-term antibiotic management due to encrusted pyelitis with a 
percutaneous nephrolithotomy (PNL) 5 years post transplantation14 and one patient (7) 
underwent a revision of the ureterovesical anastomosis. In the third patient (3), the PCN 
was removed without any additional intervention. 
One-year patient and graft survival was 100%. After five years all patients were alive 
and seven of the nine grafts (78%) were functioning. Median graft survival of the 16 
transplanted kidney grafts was 43.25 months (IQR 20-95). One patient (patient 2) 
died because of a metastasized malignancy with a functioning graft six years after 
transplantation. There was no graft loss as a result of complications that were directly 
related to the reconstructed urinary tract.
In the control group with 52 transplanted patients, the male:female ratio was 32:20. The 
median age at the time of the transplantation was 45 years (IQR 39-60) (Table 2). In ten 
grafts a PCN drain was placed between 3 and 75 days postoperatively. A total of five 
surgical re-interventions were performed in a timeframe ranging between three days 
till ten months after transplantation. In two patients, a new ureterovesical anastomosis 
was constructed and three patients were operated on account of bleeding, leakage or 
a lymphocele. For two patients a percutaneous dilatation of the ureter was performed 
successfully whereas one patient was treated with a percutaneous drainage of a 
lymphocele. 
Table 2 Characteristics case-control group characteristics
Match characteristics Case (n=13) Control (n=52) p-value
Living - Deceased 10 – 3 40 – 12 1
Donor gender male – female 6 – 7 24 – 28 1
Recipient gender male - female 8 - 5 32 - 20 1
Median follow up time, months (IQR) 53 (20-94) 56 (16-97) 0.941
Baseline characteristics
Re-transplantation(%) 3 (23) 4 (8) 0.136
Median age (years) ktx (IQR) 23 (20-45) 45 (39-60) 0.001
Median age (years) bladder reconstruction (IQR) 22 (13-30) - -
Median time (months) conduit before ktx (IQR) 87 (24-135) - -
IQR: Inter Quartile Range, ktx: kidney transplantation
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Acute rejection occurred in sixteen patients in the control group which had been 
treated with immunosuppressive medication. In three of those sixteen patients 
rejection proceeded and transplantectomy was performed one, three and five months 
after transplantation. A second kidney transplantation was performed in four patients, 
respectively two, two and a half, three and six years after the initial transplantation. 
If those were not re-transplanted, a total of seven patients were dialyzing because of 
chronic transplant failure. Five patients deceased as a consequence of diseases unrelated 
to the kidney whereas three were lost to follow up due to migration or did not visit the 
outdoor department (Table 3).
There was no significant difference in the total amount of PCN placements between the 
group with a reconstructed urinary tract and the control group (p=0.268). Five patients 
(38%) in our study group underwent a surgical re-intervention versus 5 (10%) in the 
control group (p=0.022). We could not detect a significant difference in both groups 
when we studied surgical re-interventions in detail analyzing ureter revisions or other 
re-interventions separately (respectively p=0.051 and p=0.574). Medically treated acute 
rejections occurred in idem 31% of the patients in both groups, without significant 
difference. Additionally, no significant difference was found for transplantectomy, 
dialysis and death unrelated to the kidney transplantation in both groups. Long-term 
outcome of graft survival censored for death or loss to follow-up was analyzed by a 
Kaplan Meier curve and no significant difference found (p=0.189).
Table 3 Case – control complications overview
Case (n=13) Control (n=52) p-value
PCN(%) 5 (38) 10 (19) 0.268
Surgical re-intervention total(%) 5 (38) 5 (10) 0.022
Surgical re-intervention ureter(%) 3 (23) 2 (4) 0.051
Surgical re-intervention other(%) 2 (15) 3 (6) 0.574
Dilatation ureter(%) 0 2 (4) 1
Graft loss
Rejection (medically treated)(%) 4 (31) 16 (31) 1
Transplantectomy (rejection/ no perfusion)(%) 0 3 (6) 0.605
Death not ktx related/ unknown cause(%) 1 (8) 5 (10) 1
Dialysis(%) 1 (8) 7 (13) 0.685
Loss to follow-up(%) 0 3 (6) 0.605
Graft survival(%)  
(censored for death and re-transplantation)
9 (69) 41 (79) 0.189
IQR: Inter Quartile Range, ktx: kidney transplantation
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DISCUSSION
Urological complications, including urinary tract infections in kidney transplantation 
patients are mentioned in up to 30% in the literature. These complications contribute 
significantly to morbidity and mortality rates, prolonged hospital stay and a second 
surgical intervention.15 The first successful transplantation with a reconstructed 
urinary tract was described by Kelly 6 and multiple publications thereafter demonstrate 
acceptable long-term results in this kind of transplantation.7-11, 16, 17 Still, a higher 
complication rate was mentioned and major surgical complications are reported 
between 5%-47%, mostly related to the ureteral anastomosis.1, 2, 9, 11, 17, 18 However, kidney 
transplantations with a urinary drainage into a reconstructed urinary tract are rare and 
data has mostly not been standardized.1, 7, 8, 18
Surange9 described a series of 59 kidney transplantations with an ileal conduit in 54 
patients of which 13 were children. The surgical complication rate was 47% and the total 
number of complications was 60%. Graft survival was 90% after one year, 63% after five 
years, 52% after ten years and 52% after fifteen years. Patient survival was 95% after 
one year, 83% after five years, 69% after ten years and 69% after fifteen years. Hatch11 
reviewed the experience of sixteen transplant centers, which transplanted 31 kidneys 
for 30 children. Patients had been included during a 28-year period. The authors report 
six major surgical complications postoperatively; stomal stenosis, stomal prolapse, renal 
artery stenosis, urinary leak, enterovesical fistula and wound dehiscence. Graft survival 
was 90% after one year, 78% after five years, and 60% after ten years in this group of 
children with a urinary diversion or a bladder augmentation. Hatch11 concluded that 
graft survival is not adversely affected compared to historical controls when a kidney 
transplantation is drained into a urinary conduit or augmented bladder.
Bladder reconstruction and transplantation are major interventions which require 
a high level of surgical expertise and the timing of bladder reconstructive surgery 
related to kidney transplantation is of great importance.1 An extensive medical and 
surgical history on the urinary tract may influence the results of a ureter anastomosis of 
recipients with a urinary conduit. Concerning the timing of the kidney transplantation, 
it is important to realize that when a urinary tract reconstruction is performed prior 
to the kidney transplantation, immunosuppressive medication will not influence the 
healing of the reconstructed urinary tract.19 On the other side, bladder reconstruction 
after transplantation with a stable renal function and reduced immunosuppressive 
therapy may be preferred because of optimal pre- and perioperative circumstances. 
Most centers advocate creation of the urinary conduit at least 6 weeks prior to the 
transplantation.1, 8, 10, 20
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During the transplantation an extravesical, single layer, end-to-side anastomosis of the 
graft ureter into the intestinal loop is recommended for the ureterovesical anastomosis. 
Furthermore, implantation into the native bladder portion of the reconstructed bladder 
is to be preferred.2, 9, 11 Prospective comparative studies of recent years demonstrate the 
benefits of routine stent placement.13 This may have influenced our data especially due 
to PCN placement.
Notwithstanding the relatively limited number of patients and the presence of high 
heterogeneity of reconstructions that are described in our study group, this manuscript 
reveals important data and report to our knowledge the largest series in literature about 
this topic. More percutaneous and surgical interventions were performed in patients that 
underwent a kidney transplantation into a reconstructed urinary tract. However, when 
compared to the matched group of kidney transplant patients with an anatomically and 
functionally native bladder, no higher graft loss was seen due to those interventions. 
Finally, it should be noted that important advances have been made in the entire 
medical and surgical techniques over the past decade. This includes immunosuppressive 
medication, diagnostic tests, percutaneous and surgical intervention, which has 
significantly improved the postoperative outcomes. Still it is highly recommended to 
perform kidney transplantation in patients with a reconstructed urinary tract in an 
experienced center, because of the low incidence of these cases.
CONCLUSION
Kidney transplantation on patients with bladder augmentation or urinary diversion 
is an appropriate management strategy in case of end stage renal failure. It achieves 
similar graft and patient survival. Despite an increased risk of complications and surgical 
interventions, the long-term results are encouraging.
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GENERAL DISCUSSION
In the last decades, several developments in the field of kidney transplantation have 
accelerated leading to an optimal, multidisciplinary approach. Nevertheless, urological 
complications still occur and increase the morbidity, mortality and costs.1 This thesis is 
focused on urological complications, but also donor characteristics, immunosuppression 
and graft survival on the long term are important areas, which require optimum care. 
The eminent question of this thesis is which adjustments can prevent urological 
complications in kidney transplantation in the surgical field.
Ureteroneocystostomy technique
Kidney transplantation is worldwide accepted as the best medical care in patients with 
end stage kidney disease. Optimizing transplantation and thereby the urinary continuity 
by a ureteroneocystostomy providing a watertight, tension-free, and nonrefluxing 
anastomosis with good passage of urine production and without obstruction is still a 
challenge we pursue.2 Surgical techniques have been thoroughly studied and developed 
over the past. 
In a systematic review and meta-analysis we reached level 2 of evidence by comparing 
all existing literature. In this review the extravesical technique is considered superior 
on stenosis, leakage and total number of urological complications. Though only two 
randomized controlled trials were performed by that time and showed a different 
preference for the intravesical or extravesical anastomosis and the use of a prophylactic 
ureteric stent.3, 4 Other studies that were included, were performed in different eras of 
immunosuppressive medication and had a retrospective design with additional biases.
To reach the best level of evidence we performed a randomized controlled trial 
comparing the intravesical and extravesical anastomosis in 200 consecutive kidney 
transplantations from a living donor. No differences were found regarding percutaneous 
nephrostomy placement, which is often the first sign of leakage or stenosis.1, 5 However, 
the extravesical anastomosis was performed significantly faster with fewer urinary 
tract infections compared to the intravesical anastomosis. In this study 20% of the 
patients required a percutaneous nephrostomy placement independent of the type 
of ureteroneocystostomy technique, which is rather high. This might be explained by 
the post-operative care of our kidney transplant recipients. A low threshold is taken to 
account to place a percutaneous nephrostomy, as this is considered to be minimally 
invasive. Even a slight hydronephrosis on ultrasonography leads to a percutaneous 
nephrostomy placement, either for therapeutically benefit or as diagnostic tool before 
performing a biopsy. Despite the high number of percutaneous nephrostomies, only 10 
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recipients (5%) required a radiological dilatation or surgical ureter intervention, which is 
comparable to the worldwide literature.6 
Identification of risk factors and costs of urological complications
A higher percentage of urological complications have been reported after deceased 
donor kidney donation when compared to living donor kidney donation.7, 8 Identifying 
the risk factors for urological complications is necessary to optimize the transplantation 
procedure and reduce these complications. Factors that may provoke urological 
complications, such as leakage and stenosis have not been identified in the literature. 
A possible factor may be the insufficient blood supply to the ureter after retrieval of 
the kidney.9-11 The ‘golden triangle’ is believed to be important for the blood supply 
of the ureter. Excessive dissection during organ retrieval should therefore be avoided 
and a short ureter would be favorable during transplantation to avoid necrosis of 
the distal ureter.7, 9, 11 In our study, arterial reconstruction was highly associated with 
urological complications, which is confirmed by literature.12-14 Although the type of 
ureteroneocystostomy and stent placement seem to be of influence6, 15-19 this could 
not be supported by our data. There were no differences on long-term graft survival 
between Donation after Brain Death (DBD) and Donation after Circulatory Death (DCD), 
which is also confirmed by literature. 
To evaluate the additional costs caused by urological complications we identified 
all percutaneous nephrostomies, ultrasonographies, and radiological or surgical 
interventions of 809 kidney transplantations. That way we created an overview 
of all additional costs. Our serie described an increased amount of percutaneous 
nephrostomies, especially in male patients, when compared to literature.6 Trauma during 
graft retrieval could lead to edema of the ureter causing (temporarily) hydronephrosis 
requiring a percutaneous nephrostomy, without further intervention. The high number 
of urological complications in male recipients could have an anatomical cause. The 
crossing funiculus might be an explanation for ureter obstruction in males, considering 
that the ligamentum rotundum is ligated during transplantation in females. Our series 
requires the same amount of radiological or surgical interventions when compared 
to the literature.6 Total direct medical costs made for urological complications after 
kidney transplantations were on average €2.322 per patient. This amount is probably 
an underestimation of the total amount of costs due to included areas. Rejection, 
intervention regarding arterial complications, or intervention regarding non-functioning 
grafts was not taken into account. Although urological complications are a major concern 
with morbidity, decreased quality of life and additional costs, kidney transplantation has 
an economic benefit with a significant decrease in costs as compared to dialysis.20-22
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Kidney transplantation in a reconstructed urinary tract
The first successful transplantation with a reconstructed urinary tract was described by 
Kelly,23 and multiple studies demonstrate acceptable long-term results.24-27 Still, a higher 
rate of complications is mentioned as supported by our study. Bladder reconstruction 
and transplantation are major interventions, which require a high level of surgical 
experience. The timing of bladder reconstruction related to the kidney transplantation is 
of great importance.28 Previous surgical interventions on the urinary tract may influence 
the results of a ureter anastomosis of recipients with a urinary conduit. Concerning the 
timing of the kidney transplantation, when a urinary tract reconstruction is performed 
on advance, immunosuppressive medication will not influence the healing of the 
reconstructed urinary tract.29 On the other hand, if the transplantation is performed first, 
optimal pre- and peri-operative circumstances are established with stable renal function 
and reduced immunosuppressive therapy. In our study, more percutaneous and surgical 
interventions were performed in patients that underwent a kidney transplantation with 
a reconstructed urinary tract. When compared to a matched group with an anatomically 
and functionally native bladder, there was no higher graft loss due to those interventions.
Future perspectives
Although we all agree that kidney transplantation is the optimal kidney replacement 
therapy for patients with end stage kidney disease, this field still needs further 
research. For the near future it is necessary to optimize the surgical technique in kidney 
transplantation recipients. Prospective randomized clinical trials analyzing the need 
of prophylactic stenting, type and time of removal of the stent should be of future 
interest. A decrease in urological complications will improve the quality of live, diminish 
morbidity and reduce additional costs. Future directions include an indisputable 
opinion concerning stent use, ureteral length and processes on cell level like ischemia 
or inflammation. 
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SUMMARY
This thesis describes the fundamentals of the surgical technique to perform the ureter-
bladder anastomosis and urological complications after kidney transplantation.
In chapter one a historical overview of kidney transplantation and the development 
in establishing urinary continuity is presented. Worldwide, the most accepted 
anastomosis is the ureteroneocystostomy. The two most commonly used techniques 
are the intravesical (Politano-Leadbetter) and the extravesical (Lich-Gregoir). Failure in 
this anastomosis leads to major urological complications, like leakage or obstruction 
requiring additional radiological or surgical intervention. 
Chapter two describes the existing literature in a systematic review and meta-analysis 
comparing the intravesical anastomosis to the extravesical anastomosis. The PRISMA 
statement is used to demonstrate the relative risk regarding stenosis, leakage, and 
total number of urological complications, haematuria and urinary tract infections. After 
having included a total of 19 studies, the extravesical anastomosis was superior to the 
intravesical with less stenosis, leakage and total number of urological complications. 
In chapter three we describe our performed randomized controlled trial comparing 
the intravesical anastomosis with the extravesical as described respectively by 
Politano-Leadbetter and Lich-Gregoir. Two hundred consecutive recipients of a living 
donor kidney were randomized for either intravesical or an extravesical anastomosis. 
Percutaneous nephrostomy placement was the primary outcome of this study. 
Comparing the outcomes, there was no difference in major urological complications 
like leakage or stenosis. However, the extravesical anastomosis was superior with 
significantly fewer urinary tract infections compared with the intravesical anastomosis. 
Furthermore, the extravesical anastomosis was performed significantly faster as this 
technique is surgically less complex.
In chapter four we defined independent risk factors for developing urological 
complications after 566 deceased donor kidney transplantations. Our univariate analysis 
showed an increased amount of urological complications in male donors, male recipients, 
pre-emptive transplantation, and arterial reconstruction. The multivariate analysis 
showed that male recipients and arterial reconstructions were independent risk factors 
to develop urological complications after deceased donor kidney transplantation.
In chapter five we present a retrospective study, which is performed to analyze the 
clinical outcome after kidney transplantation in 809 recipients. A total of 188 recipients 
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(23.4%) required a percutaneous nephrostomy placement while only 47 recipient 
(5.8%) required an additional radiological and/ or surgical intervention. Urological 
complications after kidney transplantation lead to an increase of costs up to on average 
€2.322 per recipient, but these complications did not influence the graft survival.
Chapter six describes our experience on kidney transplantation in patients with a 
urinary conduit. The case-control design ensured an equal comparison of patients with 
a reconstructed urinary tract, i.e. Bricker, Indiana Pouch, Mitrofanoff with recipients with 
a native bladder. An increased risk of urological complications and surgical interventions 
in the recipients with a reconstructed urinary tract was noticed. More percutaneous 
nephrostomies were placed and more surgical ureter re-interventions were performed. 
However, comparing the long term outcomes and graft survival no differences were 
found between the cases and controls. Therefore, kidney transplantation on patients 
with a reconstructed urinary tract is an appropriate management in case of end stage 
kidney disease. 
In chapter seven the studies performed in chapter two-six are discussed. In addition, 
directions for further studies are pointed out.
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CONCLUSIONS
Chapter two: The systematic review and meta-analysis shows superiority of the 
extravesical ureteroneocystostomy based on stenosis, leakage and total number of 
urological complications. 
Chapter three: The randomized controlled clinical trial shows no differences in 
the number of urological complications comparing the two most commonly used 
intravesical and extravesical ureteroneocystostomy anastomoses. However, as the 
extravesical approach is associated with fewer urinary tract infections and with a time-
sparing simplicity of the surgical technique, it may be advocated as first choice. 
Chapter four: Independent risk factors to develop urological complications in deceased 
donor kidney transplantation are recipient’s gender and arterial reconstruction of the 
graft. There were no differences in urological complications between DBD or DCD 
donors.
Chapter five: In 5.2% of all kidney transplantations a surgical ureter reconstruction 
is required with additional morbidity, decreased quality of life and additional costs. 
Nevertheless, costs made for urological complications do not outweigh the benefits of 
a kidney transplantation. 
Chapter six: Kidney transplantation in patients with a bladder augmentation or urinary 
diversion is an appropriate management strategy in case of end-stage renal failure with 
similar graft and patient survival compared to patients with a native bladder. Despite 
an increased risk of complications and surgical interventions, the long-term results are 
promising. 

General discussion and future prospectives 105
SAMENVATTING
In dit proefschrift worden de verschillende aspecten van de chirurgische techniek voor 
de ureter-blaas anastomose en urologische complicaties na een nier transplantatie 
uiteengezet.
Hoofdstuk één bevat een historisch overzicht van de niertransplantatie en de 
ontwikkelingen rondom de chirurgische techniek in het vervaardigen van de continuïteit 
van de urinewegen. Wereldwijd zijn de twee meest gebruikte technieken de intravesicale 
(Politano-Leadbetter) en de extravesicale (Lich-Gregoir) ureter-blaas anastomose. Falen 
van deze anastomose leidt tot grote urologische complicaties zoals lekkage of obstructie 
waarvoor vaak meerdere radiologische en/of chirurgische interventies noodzakelijk zijn. 
Hoofdstuk twee beschrijft de bestaande literatuur in een systematisch review met 
meta-analyse waarin de intravesicale anastomose met de extravesicale anastomose 
wordt vergeleken. De PRISMA richtlijnen zijn gebruikt om het relatieve risico van stenose, 
lekkage, totale aantal urologische complicaties, hematurie en urine weg infecties te 
beschrijven. In deze analyse waarin 19 studies geïncludeerd zijn, leek de extravesicale 
anastomose betere resultaten op te leveren ten opzichte van de intravesicale met 
minder stenose, lekkage en totaal aantal urologische complicaties. 
In hoofdstuk drie beschrijven wij onze prospectieve gerandomiseerde studie waarin de 
intravesicale met de extravesicale ureter-blaas anastomose is vergeleken. Tweehonderd 
opeenvolgende ontvangers van een nier van een levende donor werden gerandomiseerd 
voor een intravesicale of een extravesicale anastomose, met het plaatsen van een 
percutane nefrostomie katheter als primaire uitkomst maat. Bij het vergelijken van de 
uitkomsten waren er geen verschillen tussen de twee groepen wat betreft de plaatsing 
van een nefrostomie katheter. De extravesicale anastomose was echter geassocieerd 
met significant minder urineweginfecties ten opzichte van de intravesicale anastomose. 
Ook was de gemiddelde tijdsduur om een extravesicale anastomose aan te leggen 
significant korter, hetgeen verklaard kan worden door de minder complexe chirurgische 
handeling. 
In hoofdstuk vier van dit proefschrift presenteren wij een studie waarin onafhankelijke 
risicofactoren voor het ontwikkelen van urologische complicaties na een 
niertransplantatie van een overleden donor worden vastgesteld. De univariate analyse, 
verricht bij 566 niertransplantaties, liet toegenomen urologische complicaties zien bij 
mannelijke donoren, mannelijke ontvangers, pre-emptieve transplantaties en arteriële 
reconstructies. Aanvullende multivariate analyse op genoemde factoren toonde dat 
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mannelijker ontvangers en arteriële reconstructies onafhankelijke risicofactoren waren 
voor het ontwikkelen van urologische complicaties na een niertransplantatie van een 
overleden donor. 
In hoofdstuk vijf wordt een retrospectieve studie beschreven die de klinische 
uitkomsten van 809 niertransplantaties toont. Aanvullend verrichten wij een kosten 
analyse in geval van urologische complicaties. In 188 ontvangers (23.4%) van een 
niertransplantatie is een percutane nefrostomie katheter geplaatst terwijl bij 47 
ontvangers (5.8%) een aanvullende radiologische of chirurgische interventie nodig 
was. Urologische complicaties na niertransplantatie leiden tot toegenomen kosten van 
gemiddeld €2.322 per ontvanger. Echter deze complicaties zijn niet van invloed op de 
overlevingsduur van het transplantaat. 
Hoofdstuk zes beschrijft onze ervaringen van niertransplantaties bij patiënten 
met gereconstrueerde urinewegen. Een case-control ontwerp werd gecreëerd om 
ontvangers met een gereconstrueerde urineweg, zoals een Bricker, Indiana Pouch of 
een Mitrofanoff, te vergelijken met ontvangers met een natieve blaas. Een toegenomen 
aantal urologische complicaties en chirurgische interventies werd gezien in ontvangers 
van een niertransplantatie met een blaasreconstructie. In deze groep werden meer 
percutane nefrostomie katheters geplaatst en meer chirurgische ureter-interventies 
verricht. De lange termijn uitkomsten en de overlevingsduur van het transplantaat 
kwamen overeen tussen de twee patiënten groepen. 
In hoofdstuk zeven worden de bevindingen uit de hoofdstukken twee-zes 
bediscussieerd. Tevens worden enkele aanknopingspunten voor verder onderzoek 
gegeven. 
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CONCLUSIES
Hoofdstuk twee: Het systematisch review met meta-analyse toont betere resultaten van 
de extravesicale ureter-blaas anastomose, gebaseerd op het aantal stenoses, lekkages 
en totaal aantal urologische complicaties.
Hoofdstuk drie: Onze gerandomiseerde klinische studie toont geen verschil in 
urologische complicaties wanneer de intravesicale en extravesicale anastomose, 
respectievelijk volgens Politano-Leadbetter en Lich-Gregoir, met elkaar vergeleken 
worden. Desondanks had de groep met de extravesicale anastomose minder 
urineweginfecties en een kortere operatieduur door de chirurgische eenvoud van de 
anastomose.
Hoofdstuk vier: Onafhankelijke risicofactoren voor het ontwikkelen van urologische 
complicaties bij niertransplantaties van een post mortale donor zijn donor geslacht en 
arteriële reconstructie in de donor nier. Er zijn geen verschillen in het aantal urologische 
complicaties bij niertransplantaties afkomstig van een ‘heart-beating’ of een ‘non-heart-
beating’ donor.
Hoofdstuk vijf: In 5.2% van alle niertransplantaties is een chirurgische ureter-
reconstructie noodzakelijk met bijkomende morbiditeit, verminderde kwaliteit van 
leven en aanvullende kosten. Kosten in het kader van urologische complicaties wegen 
echter niet op tegen de voordelen van een niertransplantatie.
Hoofdstuk zes: Een niertransplantatie in patiënten met een blaas augmentatie of een 
gereconstrueerde urineweg is een geschikte behandeling in het geval van eind stadium 
nier falen. Hoewel er meer urologische complicaties optreden, zijn de orgaan-, en patiënt 
overleving vergelijkbaar met die van patiënten met een natieve blaas.

Chapter 9
Appendices

Appendices 111
CONTRIBUTING AUTHORS
Dr. F.J.M.F. Dor Dr. T. Terkivatan
Department of Surgery Department of Surgery
Erasmus MC University Medical Center Erasmus MC University Medical Center
Rotterdam Rotterdam
Prof.dr. J.N.M. IJzermans T.C.K. Tran
Department of Surgery Department of Surgery
Erasmus MC University Medical Center Erasmus MC University Medical Center
Rotterdam Rotterdam
H.J.A.N. Kimenai Dr. P.C.M.S. Verhagen
Department of Surgery Department of Urology
Erasmus MC University Medical Center Erasmus MC University Medical Center
Rotterdam Rotterdam
Dr. K.W.J. Klop Prof.dr. W. Weimar
Department of Surgery Department of Internal Medicine
Erasmus MC University Medical Center Erasmus MC University Medical Center
Rotterdam Rotterdam
Dr. J.I. Roodnat
Department of Internal Medicine
Erasmus MC University Medical Center
Rotterdam

Appendices 113
DANKWOORD
Het is zover, het is af! Velen hebben bijgedragen aan het tot stand komen van dit 
proefschrift. Graag wil ik iedereen bedanken voor alle hulp, interesse en steun. Een 
aantal personen wil ik in het bijzonder bedanken. 
Mijn promotor, prof.dr. J.N.M. IJzermans. Beste Jan, toen ik kwam praten over een 
onderzoekstraject van een jaar, bood je mij een promotietraject aan. Wat een 
onverwachte, maar welkome uitdaging. Bedankt voor alle vrijheid tijdens het onderzoek 
en alle motiverende en enthousiaste besprekingen die we hadden. 
Mijn co-promotor, dr. T. Terkivatan. Beste Türkan, heel veel dank voor alle begeleiding 
en je immer kritische blik. Tijdens mijn promotietraject ben je maar liefst twéé keer met 
zwangerschapsverlof geweest en toch was er altijd ruimte voor advies en overleg. Dat 
corrigeren op papier je beter afgaat dan digitaal is een feit. Ik zal mijn volledig rood 
doorstreepte documenten missen. Dankjewel voor je onuitputtende inzet. 
Graag wil ik de leescommissie, prof.dr. H.W. Tilanus, prof.dr. W. Weimar en prof.dr. 
C.H. Bangma, bedanken voor het beoordelen van dit proefschrift en deelname in de 
oppositie. 
Beste Frank, Khe en Diederik, dank voor jullie hulp, tijd en vooral alle geduld tijdens 
de uitvoering van de INEX studie. Door jullie telefoontje voor aanvang van de operatie 
kon ik op tijd paraat staan, dit geeft jullie nauwe betrokkenheid aan! Frank, altijd 
geïnteresseerd en enthousiast. Ik klopte bij jou aan om onderzoek te doen en rolde 
zo een promotietraject in. Fijn dat je zo meedenkend bent geweest gedurende mijn 
promotie. Khe, welk lootje we ook trokken, je had liever de andere gehad. Gelukkig is het 
altijd wel goed gekomen! Diederik, was het wennen om de INEX studie niet meer uit te 
hoeven voeren toen alle patiënten geïncludeerd waren? Dankjewel voor de gezelligheid 
en mooie verhalen tijdens de operaties. 
Aan alle onderzoekers van de Heelkunde in het Erasmus MC; bedankt voor alle 
betrokkenheid. Gelukkig was de afstand nooit te groot om koffie te drinken, 
verjaardagstaart te eten, langs te komen voor een gezellige babbel of hulp bij het 
onderzoek. Succes met alle onderzoeken en de verdere carrière, het komt goed! 
Mijn paranimfen verdienen een bijzondere vermelding. Lieve broer, lieve Ruben. Omdat 
je geen medische achtergrond hebt, is praten met jou een feest. Jouw nieuwe inzichten 
en opmerkingen als: ‘dan doe je toch gewoon zo….’, geven onderzoek doen een nuance 
114 Chapter 9
die niemand anders eraan kan geven. Dankjewel voor de steun en toeverlaat die je 
bent geweest de afgelopen jaren. Natuurlijk ook veel succes met je eigen carrière en 
geluk met Mariska. Ik had me geen betere grote broer kunnen wensen! Lieve Anna, mijn 
beste vriendinnetje, vanaf de dag dat we elkaar leerde kennen zat het goed! Ondanks 
onze overvolle agenda’s werd onze vriendschap niet minder hecht. Dankjewel voor alle 
gezellige etentjes, drankjes en avondjes uit. Veel succes met de laatste loodjes van je 
eigen proefschrift en je opleiding. We moeten die stedentrip nog altijd boeken (en dat 
gaat echt gebeuren!), wat een geluk dat jij naast mij staat als paranimf op deze dag!
Niet te vergeten al mijn lieve vrienden en vriendinnen, medisch en niet medisch, jullie 
gezelligheid heeft het de afgelopen jaren makkelijker gemaakt! De opvang als het ‘even 
tegenzit’ en de vreugde bij goede ontwikkelingen waren heerlijk om met jullie te delen. 
Ik heb naar alle etentjes, borrels, feestjes en uitstapjes uitgekeken en hoop dat er nog 
heel veel gaan volgen!
Lieve familie, lieve papa, met jouw kennis op veel verschillende vlakken geeft een advies 
van jou altijd een fijn gevoel! Het vertrouwen en de mogelijkheden die jij creëerde zijn 
onmisbaar geweest! Dankjewel voor de nooit eindigende support, zelfs als het niet 
precies te volgen is wat ik doe. Lieve mama, dank voor jouw onvoorwaardelijke liefde en 
interesse. Zolang ik het me kan herinneren sta je voor ons klaar. Wat een geluk hebben 
Ruben en ik met jou gehad! Zelfs nu we uitgevlogen zijn, is de interesse oneindig 
aanwezig. En lieve oma, altijd nauw betrokken bij het avontuur van de kleinkinderen! 
Opleiding is voor u altijd heel belangrijk en dat staat bovenaan. Gelukkig staan vakantie 
vieren en leuke dingen doen op een gedeelde eerste plaats. Ik hoop u nog veel 
ansichtkaarten van toekomstige vakantiebestemmingen te kunnen sturen!
Liefste Wouter, wat fijn dat jij mij hebt gevonden! Sindsdien vieren wij de hoogtepunten 
en vang je mij op bij tegenslag. Dankjewel voor het maken van de kaft, het is prachtig 
geworden! Ik ben trots op hoe jij het leven aanpakt en op je altijd open en vriendelijke 
benadering! Wat de toekomst ook gaat brengen, het wordt een mooi avontuur!


Appendices 117
LIST OF PUBLICATIONS
Urological complications after kidney transplantation clinical outcome and cost analysis 
Slagt IKB, IJzermans JNM, Verhagen PCMS, Roodnat JI, Tran TCK, Weimar W, Dor FJMF, 
Terkivatan T
Submitted
Independent risk factors for urological complications after deceased donor kidney 
transplantation 
Slagt IKB, IJzermans JNM, Visser LJ, Weimar W, Roodnat JI, Terkivatan T
PLoS One, March 2014
Intravesical or extravesical ureteroneocystostomy in living donor kidney transplantation 
recipients; A randomized controlled trial
Slagt IKB, Dor FJMF, Tran TCK, Kimenai HJAN, Weimar W, IJzermans JNM, Terkivatan T 
Kidney International, February 2014
Long-term outcome of kidney transplantation in patients with a urinary conduit: a case-
control study
Slagt IKB, IJzermans JNM, Alamyar M, Verhagen PCMS, Weimar W, Roodnat JI, Terkivatan T 
International Urology and Nephrology, April 2013
Intravesical versus extravesical ureteroneocystostomy in kidney transplantation: 
systematic review and meta-analysis 
Slagt IKB, Klop KWJ, IJzermans JNM, Terkivatan T 
Transplantation, December 2012
Other publications
Hydroxylated collagen peptide in urine improves the detection of colorectal liver 
metastases
Bröker ME, Lalmahomed ZS, Huizen NA, Dekker LJ, Ayez N, Alberda WJ, Slagt IKB, Tetteroo GW, 
Vrijand WW, Coene P, Verhoef C, Steijerberg EW, Luider TM, IJzermans JNM
Submitted
Differences in cartilage forming capacity of expanded human chondrocytes from ear 
and nose and their gene expression profiles
Hellingman CA, Verwiel ETP, Slagt IKB, Koevoet W, Poublon RML, Nolst-Trenité GJ, Baatenburg 
de Jong RJ, Jahr H, van Osch GJVM 
Cell Transplantation, 2011

Appendices 119
PHD PORTFOLIO
Name PhD-candidate: Inez Kirsten Beatrice Slagt, MD
Erasmus MC Department: Surgery
PhD period: October 2010- October 2013
Research group: Erasmus Medical Center, Department of Surgery, 
Division of Transplant Surgery
Supervisor: T. Terkivatan, MD PhD
Promotor: professor J.N.M. IJzermans, MD PhD
1. PhD training Year Workload (ECTS)
General courses
Basic Introduction Course on SPSS 2011 0.8
BROK (‘Basiscursus Regelgeving Klinisch Onderzoek’) 2011 1.5
Principles of research in medicine and epidemiology 2011 1.0
Regression analysis 2011 1.0
Biostatistics for clinicians 2012 1.0
Seminars and Workshops
Journal Club 2010-2013 3.0
Presenting Skills for Scientists 2011 1.0
Biomedical English Writing and Communication 2012-2013 4.0
CPO Minicursus voor Methodologie van Patiëntgebonden 2013 1.0
Onderzoek en Voorbereiding van Subsidieaanvragen
International conferences
ESSR, Lille (poster + oral presentations) 2012 4.0
TTS, Berlin (poster + oral presentations) 2012 4.0
ESSR, Istanbul (oral presentation) 2013 4.0
National conferences
Chirurgendagen (poster presentation) 2012 1.0
Bootcongres (2 poster presentations) 2012 1.0
2. Teaching Year Workload (ECTS)
Lecturing
Teaching (medical students, nurses in training) 2010-2013 3.0
‘Proefstuderen’ 2010-2013 2.0
Supervising practicals and excursions
Examination of Basic Life Support (EHBO) of medical students 2011-2013 1.0

Appendices 121
CURRICULUM VITAE
Inez Kirsten Beatrice Slagt was born on May 26th of 1984 
in Rotterdam. After graduation from high school at the 
Comenius College in Capelle aan den IJssel in 2002, she 
started  Psychology at the Erasmus University Rotterdam. 
A year later she started her medical studies at Erasmus 
University Rotterdam. Her medical degree was obtained in 
October 2009, where after she took up a surgical residency 
at the Albert Schweitzer Hospital in Dordrecht (dr. R.J.P. 
Oostenbroek). In October 2010 she started her PhD project 
at the Department of Surgery at the Erasmus University 
Medical Center in Rotterdam, under supervision of dr. T. Terkivatan and prof.dr. J.N.M. 
IJzermans, which resulted in this thesis. From September 2013 until August 2014 she 
worked as a surgical resident at the Department of Surgery at the Ikazia Hospital 
in Rotterdam (dr. P.T. den Hoed). At present she works as urology resident at the St. 
Elisabeth Hospital in Tilburg (dr. P.J.M. Kil).
